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ABSTRACT 
 
 
 
 Our laboratory has been studying the effects of all-trans retinoic acid 
(atRA) on the growth and differentiation of the B16 mouse melanoma cells. RA 
inhibits both anchorage-dependent and –independent growth and stimulates 
melanin production in B16 cells, which are accompanied by an increase in AP-1 
activity. To further investigate the RA-induced AP-1 activity, I established clones 
of B16 stably expressing an AP-1-luciferase reporter gene.  Treatment of these 
clones with phorbol dibutyrate (PDB), a known activator of AP-1, rapidly 
increased AP-1 activity which reached its maximum level at 2-4 h and returned to 
baseline level by 24 h. In contrast, RA treatment resulted in a slow increase in 
AP-1 activity that reached a maximum level at 48 h and was maintained for the 
duration of the treatment. I tested the importance of this increase in AP-1 activity 
for the biological effects of RA by establishing clones which stably express a 
dominant-negative version of the Fos gene (A-Fos), a component of the AP-1 
complex. Clones expressing A-Fos have greatly diminished AP-1 activity and a 
markedly decreased sensitivity to RA-induced growth inhibition and 
differentiation. Our observations suggest that RA-induced AP-1 activity plays an 
important role in the biological changes mediated by RA in B16 cells. 
 The AP-1 transcription complex consists of homodimers and heterodimers 
of Jun and Fos family members, or ATF2 bZIP proteins. Malignant B16 
melanoma cells have a much higher amount of ATF2 compared to non-malignant 
mouse melanocytes. Over 70% of the ATF2 protein in B16 cells is in the 
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phosphorylated form, while only 16% of the total ATF2 is phosphorylated in the 
mouse melanocytes. RA treatment of B16 cells for 48 h decreased ATF2 
phosphorylation by 60%. Investigation of the signaling pathway involved in RA-
dependent decrease in ATF2 phosphorylation demonstrated that RA inhibits 
activation of the MAP kinase p38. These data suggest that RA inhibits ATF2 
phosphorylation most likely via its ability to block the activation of p38. In 
addition, RA increases the sensitivity of B16 cells to the chemotherapeutic drug, 
taxol, likely by the way of decreasing ATF2 phosphorylation. 
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REVIEW OF THE LITERATURE 
 
 
Vitamin A 
 
Vitamin A is one of a group of substances that have similar structures and 
biological activities and that are known collectively as retinoids (Kaegi, 1998). 
Vitamin A was discovered in 1913 as a fat-soluble substance required for normal 
growth, bone development, vision and reproduction and for the maintenance of 
the integrity of the skin and mucous membranes (Kaegi, 1998; Loescher et al., 
1984). As neither embryonal nor adult cells have the capacity to synthesize 
vitamin A de novo, vitamin A must be present in the diet as either vitamin A 
alcohol (retinol) and its esters or β-carotene (a provitamin hydrolyzed in the 
intestine to vitamin A) (Bollag, 1983). The recommended adult daily intake of 
vitamin A is 800-1000 Retinol Equivalents (RE), where 1 RE = 3.33 IU’s. Of the 
naturally occurring retinoids, the most potent is retinoic acid (RA), followed by 
retinol, retinyl palmitate, and retinyl acetate. The link between vitamin A and 
cancer in mammals was initially reported in 1926 when rats, fed a vitamin A-
deficient diet, developed gastric carcinomas (Loescher et al., 1984). The 
relationship between vitamin A and human cancer was first investigated in 1941 
by Abelsetal who found low plasma vitamin A levels in patients with 
gastrointestinal cancer (Loescher et al., 1984). 
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Origin and metabolism of vitamin A 
 
 
Retinoids play a central role in many essential biological processes, such 
as embryogenesis (Gudas, 1994), vision (Wald, 1968), cell growth and 
differentiation (Deluca, 1991), and reproduction (Srikantia, 1975). The main 
dietary sources of vitamin A are eggs, milk, butter and fish-liver oils. The 
provitamin β-carotene is from fruits and vegetables. The major pathways for 
retinoid transport in the body are shown in Figure 1. After uptake by the intestinal 
mucosa cells, dietary retinyl esters are hydrolyzed to retinol in the intestinal 
lumen prior to absorption by enterocytes. Carotenoids are absorbed and then 
partially converted to retinol in the enterocytes. In enterocytes, retinol is esterified 
to fatty acids before incorporation into chylomicrons. Chylomicrons then reach 
the general circulation by way of the intestinal lymph, and chylomicron remnants 
are formed in blood capillaries. Chylomicron remnants, which contain almost all 
of the absorbed retinol, are mainly taken up and stored by the liver. In liver 
parenchymal cells, retinyl esters are rapidly hydrolyzed to retinol, which then 
binds to retinol-binding protein (RBP). Retinol-RBP is secreted and transported to 
hepatic stellate cells. These cells secrete retinol-RBP directly into plasma. Most 
retinol-RBP in plasma is reversibly complexed with transthyretin. How retinol gets 
into the target cells is still controversial. One theory is that the uncomplexed 
retinol-RBP is taken up in a variety of cells by cell surface receptors specific for 
RBP. Most of the retinol taken up will then recycle to plasma, either on the “old” 
RBP or bound to a newly synthesized RBP (Wake, 1980). In the target cells, 
retinol is oxidized to retinal and retinoic acid (RA) (Blomhoff, 1993).  
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Figure 1
Major pathways for retinoid transport in the body 
 
Image inspired by Dr. Rune Blomhoff. Transport and 
metabolism of Vitamin A. Symposium held at Marabou, 
Sundbyberg, Sweden. 1993. (CM: chylomicron, CMR: 
chylomicron remnant, TTR: transthyretin, RE: retinyl ester, 
RBP: retinol-binding protein, ROH: retinol, RA: retinoic acid) 
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Mechanism of retinoid action 
 
Before vitamin A can fulfill its functions in the body, it undergoes complex 
processes which involve considerable metabolic activity. One process is to 
produce the active retinoids, such as all-trans retinoic acid. The other process is 
to convert the provitamin carotenes into retinol, the parent vitamin A compound. 
Specific retinoid-binding proteins participate in these metabolic transformations.  
Four cellular retinoid-binding proteins have been well characterized. They 
are cellular retinol-binding protein (CRBP), cellular retinol-binding protein, type 
two (CRBPII), cellular retinoic acid-binding protein (CRABP), and cellular retinoic 
acid-binding protein type two (CRABPII) (Ong et al., 1994; Demmer et al., 1987). 
A fifth protein, cellular retinal-binding protein is restricted to visual tissue (Saari, 
1994). CRBP and CRABP have higher affinity for retinol and retinoic acid, 
respectively, than the type two forms (Levin et al., 1988; Li et al., 1991; Fogh et 
al., 1993). Each of the binding proteins functions as a cellular reservoir of 
retinoid, keeping the concentration of free retinoid very low, protecting the cells 
from the detergent-like properties of the free retinoids. The other function of 
these proteins is to serve as retinoid transfer agents. For example, CRBP 
interacts at a specific membrane site to allow transfer of its bound retinol to the 
RBP. CRABP and CRABPII bind the dominant hormonally active form of vitamin 
A, retinoic acid, and their function may involve direct interaction with nuclear 
retinoic acid receptors, either for transfer of retinoic acid to or removal of retinoic 
acid from these proteins (Fogh et al., 1993). In addition, retinoid-binding proteins 
function as modulators of retinoid metabolism. CRBP directs the 
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esterification/deesterification of retinol and the subsequent oxidation of that 
retinol to retinal and then retinoic acid, the main hormonally active form of vitamin 
A (Napoli et al., 1991; Napoli, 1993; Ong, 1994). CRABP serves to accelerate the 
metabolism of retinoic acid to more polar metabolites (Fiorella et al., 1991). 
In the early 1980s, several laboratories (Evans, 1988; Green et al., 1988) 
found that retinoids regulated gene transcription through the mediation of nuclear 
receptors. In 1987, the first human nuclear RA receptor (hRARα) was isolated 
independently by two laboratories (Giguere et al., 1987; Petkovich, 1987). This 
receptor shares similar structural characteristics with other members of the 
steroid receptor superfamily, such as a DNA-binding domain and a ligand-binding 
domain. Subsequently, two additional RAR regulatory genes (RARβ, RARγ) have 
been isolated, and homologues characterized in other mammals, avians, and 
amphibians (Mangelsdorf et al., 1994). In 1990, a second class of retinoid-
responsive transcription factors, the human retinoid X receptor (hRXRα), was 
discovered (Mangelsdorf et al., 1990). This class also contains three genes, 
termed RXRα, β, and γ, and homologues found in other mammals, avians, and 
amphibians (Mangelsdorf et al., 1994).  All-trans RA (atRA) is the main activator 
of RARs, but not RXRs (Mangelsdorf et al., 1990). Nine-cis RA (9cRA), a 
stereoisomer of atRA, binds and activates transcription from both RARs and 
RXRs (Heyman et al., 1992; Levin et al., 1992).  Retinoid X receptor (RXR) 
serves as a common heterodimeric partner for retinoic acid receptors (RARs), 
thyroid hormone receptor (TR), vitamin D receptor (VDR), and PPAR 
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(peroxisome proliferator activated receptor), as well as numerous orphan 
receptors (LeBlanc et al., 1995).  
Members of the nuclear receptor superfamily modulate gene expression 
by binding as homo- or heterodimers to specific DNA sequences known as 
hormone response elements (HREs). The discovery of retinoid receptors has 
allowed the identification of the retinoic acid response element (RAREs) in the 
promoter regions of the target genes. Like the HREs for the other members of 
the nuclear receptor superfamily, the retinoid response elements consist of a 
minimal half-site consensus sequence (AGGTCA) configured into a variety of 
structural motifs, including direct repeats (DR) and palindromes (Umesono et al., 
1988; Umesono et al., 1991; Naar et al., 1991).  The strongest activation by 
RAR-RXR is mediated through RAREs that are direct repeats of the consensus 
sequence (AGGTCA) spaced by a defined number of nucleotides as follows: 
RXREs - DR-1; RARE II - DR-2; and RARE I - DR-5 (Mangelsdorf et al., 1994). 
The retinoid receptor signaling pathways are shown in Figure 2. 
In the absence of ligands, RAR-RXR dimers remain bound to their DNA 
response element, resulting in repression of the target genes due to the 
recruitment of a multisubunit repressor complex (Nagy et al., 1997). In 1995, two 
transcriptional corepressors, SMRT (silencing mediator for retinoid and thyroid 
hormone receptors) and N-CoR (nuclear receptor corepressor), were identified. 
These corepressors associate with nonliganded receptors resulting in 
suppression of basal transcriptional activity (Chen et al., 1995; Chen et al., 1996; 
Horlein et al., 1995; Sande et al., 1996). SMRT functions as a hormone-
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dependent adaptor that associates with both mSin3 (mammalian homolog of the 
yeast global-transcriptional repressor Sin3p) and HDAC (histone deacetylase) 
through its repressor domain and with receptors via a distinct interaction domain. 
In this complex, HDAC activity creates a repressive chromatin environment. 
Retinoic acid receptor (RAR) ligand binding destabilizes the corepressor-binding 
surface and induces conformational changes, such as the movement of helix 
H12, the carboxy-terminal helix, to generate a novel interaction surface for 
coactivators. H12 in the liganded LBD (ligand binding domain) contributes to the 
coactivator interface. Therefore, two mechanisms are involved in the activation of 
RAR-RXR transcription: derepression, caused by chromatin decondensation, and 
a receptor-dependent increase in transcription initiation (Glass et al., 2000; 
Rachez et al., 2001; Ito et al., 2001).  
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Figure 2. Two retinoid signaling pathways. 
  
RXR functions as a ligand-dependent transcription factor (as a 
homodimer), and as an active partner with other members of the nuclear receptor 
superfamily (as a heterodimer). Thus, RXR mediates two retinoid signaling 
pathways: RXR homodimer and RXR-RAR heterodimer. 9cRA promotes RXR 
homodimer formation (Zhang et al., 1992), atRA, low concentrations of 9cRA 
and/or high RAR concentrations stabilize the RAR-RXR heterodimer. In addition, 
RAR-RXR heterodimer can act as a repressor of RXR homodimer function 
(Mangelsdorf et al., 1991). In vitro RAR-RXR heterodimers are more stable and 
have higher affinity for DNA than the RXR homodimer (Zhang et al., 1992; 
Durand et al., 1992). 
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Figure 2 
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Retinoic acid is essential for life  
 
 RA functions as a morphogen (Crick, 1970) to exert profound effects on 
embryogenesis and organogenesis. For example, it can proximalize (Maden, 
1984), posteriorize (Maden (a), 1983) and ventralize blastemal cells to respecify 
(Maden (a), 1983) each of the cardinal axes of the limb and regenerate 
amphibian limb (Niazi et al., 1978). RA effects are concentration, time and stage-
dependent (Maden, 1982; Maden (b), 1983). Vitamin A deficiency in animals 
causes severe malformation, indicating that retinoids are important during 
embryogenesis (Blomhoff et al., 1990). In contrast, high concentrations of 
retinoids are teratogenic. Exposure to retinoic acid or large doses of vitamin A at 
critical stages of development halts neural crest cell migration, and leads to 
absent or defective ears, absent or small jaws, cleft palate, aortic arch 
abnormalities, thymic deficiencies, and abnormalities of the central nervous 
system (Willhite et al., 1986) 
 
 
Retinoids and cancer 
 
 Retinoids have been demonstrated to inhibit development of a number of 
different types of tumors (Aylsworth et al., 1986; Munker et al., 1987) and to 
inhibit the growth of a variety of neoplastically transformed cells, in some cases 
inducing differentiation (Breitman et al., 1980; Edward et al., 1988; Strickland et 
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al., 1980). For example, acute promyelocytic leukemia (APL) can be effectively 
eradicated by retinoid treatment combined with chemotherapy (Fenaux et al., 
2001). The molecular mechanism involved in this effect is that retinoids 
contribute to the differentiation and apoptosis of APL blasts (Mann et al., 2001). 
Recently, retinoids have been showed to be promising for the treatment of 
preneoplastic oral, bronchial and head and neck lesions, preventing them from 
progression to frank malignant tumors (Hong et al., 1986; Hong et al., 1990; 
Benner et al., 1994; Lotan et al., 1995). The 13-Cis RA in combination with 
interferon α has been successfully used to control cervical cancer (Lippman et 
al., 1992). In addition, the combination of retinoids/rexinoids with chemotherapy, 
interferons, or tamoxifen has been used to treat breast cancer (Lawrence et al., 
2001). Retinoids are effective in delaying the development of skin cancer in 
individuals with xeroderma pigmentosum, an inherited predisposition to UV-
induced cancers (Kraemer et al., 1988).  Retinoids are now routinely used for the 
treatment of three precancerous lesions – leukoplakia, actinic keratosis and 
cervical dysplasia. Further clinical trials of RA combinations are now in progress, 
such as in patients with ovarian cancer (Torrisi et al., 2000; Veronesi et al., 2001; 
Zhang et al., 2000), bladder cancer (Torrisi et al., 2000; Clifford et al., 2001), 
non-small-cell lung cancer (Lippman et al., 2001; Recchia et al., 2000), and 
thyroid cancer (Schmutzler et al., 2000; Grunwald (a) et al., 1998; Grunwald (b) 
et al., 1998). At present, the major goal of retinoid research is to understand how 
the anticancer effects of retinoids are regulated and how cancer cells become 
resistant to retinoids. These studies could lead to synthesis of new synthetic 
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retinoids with few side effects and high efficacy, allowing the retinoids to be more 
widely used. For example, since the anticancer effects of retinoids are mainly 
mediated by their nuclear receptors RARs and RXRs, synthesis of RAR-selective 
retinoids can reduce side effects since many of the unwanted effects of retinoids, 
such as retinoic acid, are due to their activation of all RAR subtypes (Niles, 
2002).   
 
 
AP-1 Transcription Factor 
 
 AP-1 is an acronym for activating protein-1, one of the first mammalian 
transcription factors to be identified (Angel et al., 1991). The transcription factor 
AP-1 was first detected as having DNA binding activity specific for positive 
regulatory elements in the SV40 early promoter. Additional research revealed 
that AP-1 was important not only for the basal activity of the SV40 early 
promoter, but also for the induction of gene expression in response to tumor-
promoting phorbol esters, such as tetradecanoyl-13-phorbol acetate (TPA). 
Therefore, the name TRE (TPA response element) has been used for its 
recognition site (Angel et al., 1987).  Instead of being a single protein, the AP-1 
transcription family is  large, consisting of  Jun (v-Jun, c-Jun, Jun B, Jun D), Fos 
(v-Fos, c-Fos, Fos B, Fra1, Fra2) and ATF (activating transcription factor) (ATF2, 
ATF3/LRF1, B-ATF) proteins that bind to a common DNA site, the AP-1 binding 
site (Angel et al., 1991; Vogt et al., 1990). AP-1 subunits belong to bZIP (basic 
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region leucine zipper) family, which share the same structural domains for 
dimerization and DNA binding: the basic region binds the DNA-contact surface, 
whereas the leucine zipper enables the formation of homo- and heterodimeric 
complexes with other bZIP proteins. Dimer formation is essential for DNA binding 
(Wisdom, 1999). The structures of Jun, Fos and ATF family members are shown 
in Figure 3. The Jun protein is a central part of all AP-1 transcription complexes 
(Karin, 1995). Jun proteins not only form very stable heterodimers with Fos- and 
ATF- family members, they can also form homodimers among themselves 
(Kouzarides et al., 1988; Smeal et al., 1989; Hai et al., 1991). ATF proteins also 
form stable homodimers (Dorsey et al., 1995). Fos proteins, which cannot 
homodimerize, form stable heterodimers with Jun proteins which enhances their 
DNA binding activity (Zerial et al., 1989). Jun:Jun and Jun:Fos dimers bind with 
high affinity to the seven base pair consensus sequence TGAGTCA (TRE), 
whereas Jun:ATF dimers or ATF homodimers prefer to bind to the octameric 
cyclic AMP-response element (CRE). This element has the basic sequence 
TGACGTCA (Hai et al., 1989). However, c-Jun:ATF2 and ATF2:ATF2 show 
differences in their relatively affinities for the more degenerate 8 bp CRE ( 
Benbrook et al., 1994; Benbrook et al., 1990). This variation in DNA binding site 
specificity and dimer partner provides AP-1 family members with a high level of 
flexibility in gene regulation. The activity of Jun:Fos and Jun:ATF2 complexes 
can be regulated at multiple levels: (i) changes in Jun, Fos, and ATF transcription 
and mRNA stability; (ii) regulation of Jun, Fos, and ATF protein stability; (iii) post-
translational modifications of Jun, Fos, and ATF proteins that modulate their 
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transactivation potential; and (iv) protein-protein interactions with other 
transcription factors that can synergize or interfere with AP-1 activity. The AP-1 
transcription factors mediate gene regulation in response to specific growth 
factors, cytokines, tumor promoters, carcinogens and oncoproteins. Based on 
these facts, AP-1 has been considered a key regulator of various complex 
biological processes, such as cell proliferation, transformation, differentiation, 
apoptosis and protection against DNA-damaging agents (Angel et al., 2001). 
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Figure 3.  Structures of Jun, Fos and ATF proteins 
  
 AP-1(activating protein-1) is a collective term referring to dimeric 
transcription factors composed of Jun, Fos or ATF (activating transcription factor) 
subunits which belong to a family of basic region-leucine zipper proteins. The 
leucine zipper mediates dimerization; DNA binding to the AP-1 target sequence 
is mediated by residues of the adjacent basic region, which make direct base 
contacts. Like most other transcription factors, Fos, Jun and ATF2 proteins are 
modular, the DNA binding and transcriptional activation domains are physically 
separable. Jun proteins can homodimerize among themselves and also form 
very stable heterodimers with Fos- and ATF- family members. ATF proteins, but 
not Fos proteins, also form stable homodimers. Jun:Jun and Jun:Fos dimers 
preferentially bind to the TRE (TGACTCA); whereas Jun:ATF dimers or ATF 
homodimers prefer to bind to CRE (TGACGTCA).  
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Regulation and function of Jun family proteins 
 
 The Jun protein was originally identified as an oncoprotein encoded by a 
cellular insert in the genome of avian sarcoma virus 17, an acutely oncogenic 
retrovirus isolated from a spontaneous tumor in chickens (Cavalieri et al., 1985; 
Maki et al., 1987). The human Jun gene maps on chromosome 1p32-p31, a 
chromosomal region involved in both translocations and deletions in human 
malignancies (Haluska et al., 1988). The sequence of the genomic clone was 
found to be contiguous with the sequence of the JUN cDNA, which suggested 
that the Jun gene has no introns (Hattori et al., 1988). There are three protein 
members of the Jun family of proteins: c-Jun, JunB and JunD. The predicted 
molecular weight of Jun protein is 41.9 kDa. Jun proteins belong to the bZip 
family, which allows them to form homodimers and heterodimers with other bZip 
proteins. The leucine zipper domain required for the dimerization is located at the 
C-terminal region (Lanschulz et al., 1988). A basic region, serving as the DNA 
binding domain, is located to the N-terminal site of the leucine zipper. All Jun 
proteins from different species contain an N-terminal JNK docking domain 
adjacent to the JNK phosphorylation site, Ser63/73.  
 C-Jun and v-Jun can induce oncogenic transformation; JunD shares the 
potential to induce oncogenic transformation with Jun (Castellazzi et al., 1991; 
Hartl et al., 1992; Kameda et al., 1993; Vandel et al., 1996; Vandel et al., 1995). 
The function of JunB is somehow complicated. Replacement of c-Jun by JunB 
prevents most of the developmental and cellular defects associated with a loss of 
c-Jun (Passegue et al., 2002). Transgenic mice specifically lacking JunB 
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expression in the myeloid lineage developed a transplantable myeloproliferative 
disease, eventually progressing to blast crisis, which resembled human chronic 
myeloid leukemia; ectopic expression of JunB fully reversed the immature and 
hyperproliferative phenotype of Jun B-deficient myeloid cells (Passegue et al., 
2001). These studies suggested that in the absence of c-Jun, JunB may function 
as a positive growth regulator. However, in the presence of c-Jun, JunB has 
opposite effects. Murine primary fibroblasts lacking Jun D displayed p53-
dependent growth arrest, upregulated p19 (ARF) expression, and premature 
senescence (Weitzman et al, 2000).  
 c-Jun is essential for normal mouse development since homozygous Jun-/- 
mouse embryos die after 12-14 days at mid-to-late gestation (Kerppola et al., 
1996; Hilberg et al., 1993; Johnson et al., 1993). c-Jun -/- embryonic stem cells 
differentiate into functional germ and somatic cells but not into hepatocytes. 
Primary fibroblasts from c-Jun-/- embryos are completely defective in their 
proliferation. In contrast, cells that constitutively express c-Jun fail to arrest and 
continue to proliferate after UV exposure (Shaulian, 2000). It has been well 
known that Jun regulates cell proliferation, apoptosis and transformation. Jun 
promotes cell cycle transition from the G1 phase to S phase by up-regulating 
cyclin D1 expression and antagonizing the function of p53 and p21 on apoptosis 
(Schreiber, 1999; Wisdom et al., 1999). The direct effects of c-Jun on apoptosis 
result from transcriptional regulation of pro- and anti-apoptotic gene products, 
such as FasL, Bim, Bcl3, or Fas. c-Jun-mediated induction of pro-apoptotic 
genes (FasL, Bim) supports apoptosis (Shaulian et al., 2001), whereas 
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upregulation of anti-apoptotic gene products and down-regulation of pro-
apoptotic gene products (Bcl3, Fas) promotes cell survival (Rebollo, 2000). The 
importance of these functions is demonstrated by the observation that 
hepatocytes derived from c-Jun-/- embryos undergo massive apoptosis (Hilberg 
et al., 1993; Eferl, 1999). The oncogenic potential of Jun has been revealed by 
overexpression experiments. Very interestingly, all Jun proteins can cooperate 
with Ha-Ras in rat embryo fibroblast transformation, however c-Jun is the most 
potent family member (Vandel, 1996). This effect of Jun may partially be through 
the induction of downstream target genes, such as JAC (Jun-activated gene in 
chicken embryo fibroblasts), or HB-EGF (heparin-binding epidermal growth 
factor-like growth factor) (Hartl et al., 2001; Fu et al., 1999).  Overexpression of 
Jun has been observed in certain human cancers. However, no mutation, 
rearrangement or amplification of the Jun gene has been reported.  
 The c-Jun gene is expressed in many cell types at low levels. It has been 
characterized as an “immediate-early” gene whose transcription is rapidly 
induced, independently of de novo protein synthesis (Treisman, 1992). 
Therefore, c-Jun expression is highly responsive to external growth signals, 
cytokines and UV-irradiation (Karin, 1995). Major induction of the c-Jun gene is 
achieved through one cis-element, the c-Jun TRE, which differs from the 
consensus TRE sequence by 1-base pair insertion (Angel et al., 1988). Due to 
this subtle difference, it is proposed to be recognized by c-Jun:ATF2 
heterodimers, instead of conventional AP-1 complexes (van Dam et al., 1993). 
Another part of the increase in AP-1 activity is due to c-Jun phosphorylation. 
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There are two sites of phosphorylation in the c-Jun protein. One cluster of sites is 
located next to the basic region; phosphorylation at these sites inhibits DNA 
binding by c-Jun homodimers but not by c-Jun:c-Fos heterodimers (Boyle et al., 
1991). ERK1 and ERK2 MAP kinases can phosphorylate the inhibitory sites 
located next to the C-terminal DNA binding domain (Minden et al., 1994; Chou et 
al., 1992). Alternatively, phosphorylation of c-Jun at Ser63 and Ser73, which are 
located within its transactivation domain, promote its ability to activate 
transcriptional activity as either a homodimer (Pulverer et al., 1991; Smeal et al., 
1991) or a heterodimer with c-Fos (Deng et al., 1994). The modulation of 
phosphorylation is carried out by a two-step mechanism: first, c-Jun N-terminal 
kinase (JNK) associates with c-Jun at the JNK docking site, and second, JNK 
phosphorylates c-Jun. Consistent with this mechanism, the docking site for JNK 
is separable from the phosphorylation sites (Hibi et al., 1993; Kallunki et al., 
1994). Following phosphorylation of its N-terminal sites, c-Jun can interact with 
the CBP/P300 family of coactivators (Arias et al., 1994; Kwok et al., 1994), which 
connect the phosphorylated activation domains of c-Jun to the basal 
transcriptional machinery (Arias et al., 1994). Another coactivator that interacts 
with the N-terminal activation domain of c-Jun is JAB1 (Jun activation domain 
binding protein 1) (Claret et al., 1996). The mechanism by which it enhances 
their ability to activate transcription is through stabilization of the AP-1 complexes 
(Claret et al., 1996). In addition to being activated by co-regulators, AP-1 activity 
is also inhibited by other proteins (Gottlicher et al., 1998). For example, the 
glucocorticoid receptor interferes with Jun activity (Gonzalez et al., 2000). The 
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mechanism of this interaction is complex; it may involve the regulation of JNK. 
The inhibition of Jun induced by the glucocorticoid receptor affects Jun-induced 
oncogenic transformation. The transcriptional activity of c-Jun:c-Fos is inhibited 
by the interferon-inducible p202 (Min et al., 1996). It was shown that p202 
directly interacts with c-Jun and c-Fos. The mechanism of downregulation of AP-
1 activity by p202 may include the inhibition of DNA binding of c-Jun homodimers 
or heterodimers (Min et al., 1996). 
 
 
Regulation and function of c-Fos 
 
The c-Fos protooncogene (Curran et al. 1984) was originally identified as 
the cellular counterpart of the viral oncogene (Curran et al. 1982) carried by 
Finkel-Biskis-Jinkins (FBJ) murine osteosarcoma virus (Finkel et al. 1966). The 
Fos gene encodes a 55 kDa nuclear protein which dimerizes with the Jun family 
proteins, such as c-Jun, JunB and JunD, to form high-affinity heterodimer-
transcription factor AP-1 complexes (Curran et al. 1988). Fos-related proteins do 
not form stable homodimers because of an apparent conformational form that 
precludes complementary leucines from getting close enough to each other to 
form a stable bond (Suzuki et al., 1994). The Fos family contains four proteins: c-
Fos, Fos B, Fra-1 and Fra-2. They can be subdivided into two groups, based on 
their ability to transform rodent fibroblasts; transforming (c-Fos and Fos B) and 
non-transforming (Fra-1 and Fra-2) proteins. The Fos protooncogene is activated 
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in cells stimulated to grow and to differentiate. Often Fos induction precedes 
induction of other protooncogenes, i.e. it is classified as an immediate early 
response gene. The abundance of c-Fos protein is most commonly regulated by 
controlling the transcription of its gene. Treatment of cells with different stimuli 
induces c-Fos transcription very rapidly and transiently (Piechaczyk et al., 1994; 
Treisman, 1992). Three cis elements mediate c-Fos induction. One is a CRE that 
is likely to be occupied by CREB (CRE-binding protein) or ATF proteins. This 
response element mediates C-Fos induction via cAMP- and Ca2+-dependent 
signaling pathways in response to neurotransmitters and polypeptide hormones 
(Sheng et al., 1991).  Another cis element that regulates c-Fos transcription is an 
SIE (Sis-inducible enhancer), which is recognized and activated by the STAT 
(signal transducer and activator of transcription) group of transcription factors 
(Damell et al., 1994). The third cis element is SRE (serum-response element), 
which is activated by a dimer of serum-response factor (SRF). The SRF recruits 
the monomeric ternary complex factors (TCFs) (Sheng et al., 1991). SREs are 
important mediators for c-Fos induction by various extracellular stimuli, such as 
UV irradiation (Buscher et al., 1988). Following mitogenic stimulation, Elk-1, one 
of TCFs (Treisman, 1994), is rapidly phosphorylated by the ERK group of MAPKs 
(Gille et al., 1992; Marais et al., 1993). ERK activation increases AP-1 activity via 
increased synthesis of c-Fos. c-Fos proteins then translocate to the nucleus and 
bind with pre-existing Jun proteins to form AP-1 heterodimers that are more 
stable than Jun homodimers (Smeal et al., 1989).  
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Analogous to Jun proteins, the activities of both pre-existing and newly 
synthesized c-Fos are modulated through their phosphorylation. Although there 
is similarity between the two phosphoacceptor sites of c-Jun (Ser73) and c-Fos 
(Thr232) (Sutherland, 1992), Thr232 of c-Fos is not phosphorylated by JNK but 
by a novel 88 kDa MAPK termed FRK (Deng et al., 1994). FRK is rapidly 
stimulated in response to Ha-Ras activation by growth factors. The mechanism 
by which phosphorylation at Thr232 stimulates c-Fos transcriptional activity is not 
clear.  
 Unlike Jun protein, the knockout of the mouse c-Fos gene demonstrated 
that c-Fos is not essential for viability (Johnson et al., 1992). c-Fos -/- mice, 
although viable, exhibit defects in bone formation (develop osteoporosis) and the 
central nervous system (growth-retarded) (Reimold et al., 1996). These results 
demonstrate that c-Fos proteins are involved in bone formation, gametogenesis 
and certain neuronal functions (Johnson et al., 1992). In addition, overexpression 
of c-Fos in bone tissue resulted in development of osteosarcomas (Wang et al., 
1995).  
 
 
Regulation and function of ATF2 
 
 Activating transcription factor 2 (ATF2) belongs to the family of the 
ATF/cAMP-response element-binding proteins containing the basic region-
leucine zipper motifs (Maekawa et al. 1989; Hai et al. 1989). The cAMP response 
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element (CRE) is an octanucleotide motif (TGACGTCA) that mediates diverse 
transcriptional regulatory effects. Multiple CRE-binding proteins have been 
identified. The ATF2 gene was cloned by Maekawa et al. (1989). By in situ 
hybridization, Diep et al (1991) mapped the ATF2 gene to 2q24.1-q32. ATF2 
protein was isolated by Bailey et al., and found to have a molecular weight of 70 
kDa. ATF2 plays an important role in the stress response, cell growth and 
differentiation, and immune response (Livingstone et al. 1995; Van Dam et al. 
1995). ATF2 target genes include tumor necrosis factor α (TNFα) (Tsai et al. 
1996), transforming growth factor β (Kim SJ, et al. 1992), cyclin A (Shimizu et al. 
1998), E-selectin (Read et al. 1997), DNA polymerase β (Narayan et al. 1994), 
and c-Jun (Van Dam et al. 1993). ATF2 interacts with a variety of viral 
oncoproteins and cellular tumor suppressors (Gupta et al., 1995; Van Dam et al., 
1995; Livingstone et al., 1995). Therefore, ATF2 has been implicated in cellular 
proliferation in vitro and tumor formation in vivo through its cooperation with v-
Jun (Huguier et al., 1998). Similarly, c-Jun:ATF2 dimers have been implicated in 
oncogenesis (Van Dam et al., 2001). Kawasaki et al (2000) reported that the 
middle portion of ATF2 (residues 112-350) has intrinsic histone acetyltransferase 
(HAT) activity that specifically acetylates histones H2B and H4 in vitro. 
Phosphorylation of ATF2 controls its intrinsic HAT activity and its action on CRE-
dependent transcription. ATF2 -/- mice exhibit a phenotype similar to c-Fos -/- 
mice, which display defects in bone formation and the central nervous system. In 
addition, ATF2 has been found to play an important role in melanoma 
proliferation (Recio et al., 2002) and resistance to treatment (Yang et al. 1996; 
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Ronai et al. 1998). It has been reported that hypophosphorylation or 
transcriptionally inactive forms of ATF2 reduce TNFα expression, resulting in 
sensitization of melanoma to chemotherapy and radiotherapy via increased 
apoptosis (Ronai et al., 1998; Ivanow et al., 1999). 
 Together with bZIP proteins of the Fos and Jun families, ATF2 constitutes 
the AP-1 transcription factor complex. Unlike Jun and Fos, expression of ATF2 is 
constitutive (Karin, 1995). The biological activity of ATF2 is regulated post-
translationally by phosphorylation. Under nonstressed normal growth conditions, 
ATF2 exhibits a low level of transactivation because of an intramolecular 
inhibitory interaction in which the C-terminal DNA binding domain is bound to the 
N-terminal transactivation domain (Li et al. 1996). Upon stress induction, 
phosphorylation of amino acid residues Thr69 and Thr71 releases the 
intramolecular inhibition (Abdel-Hafiz et al. 1992). The phosphorylation is mainly 
mediated by stress-activated protein kinases (SAPK) including JNKs and p38 
MAP kinases (Raingeaud et al. 1996). The model of activation of ATF2 is shown 
in Figure 4. In addition, stimulation of ATF2 transcriptional activity can result from 
its interaction with several transcription factors, such as c-Jun (Van Dam et al. 
1993), NFkB (Kaszubska et al. 1993), retinoblastoma protein (Kim et al. 1992), 
and c-Myc (Miethe et al. 2001). Transcriptionally active ATF2 recognizes and 
binds specific CRE motifs as a homodimer or heterodimer form (Hai et al., 1989; 
Van Dam et al., 1995), and regulates a wide set of genes that play roles in the 
regulation of cell growth, differentiation, immune response and apoptosis.  
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Figure 4. The model of ATF2 activation 
 
 ATF2 is a cellular basic region leucine zipper transcription factor that can 
mediate a variety of transcriptional responses, including proliferation, 
differentiation, immune response and apoptosis. In the absence of appropriate 
stimuli, ATF2 is transcriptionally inactive because of its intramolecular inhibition, 
in which the ATF2 activation domain and bZIP domain specifically bind to each 
other. ATF2 is known to acquire its transcriptional activity upon phosphorylation 
by MAP kinases, including JNK and p38 kinases. Phosphorylation leads to ATF2 
conformational changes, which releases the intramolecular inhibition (Li et al., 
1996). 
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Figure 4 
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Melanoma skin cancer 
  
Melanoma is the most serious form of skin cancer. It begins in 
melanocytes – cells that make the skin pigment (melanin). In the United States, 
the number of new melanomas diagnosed is rapidly increasing. Since 1973, the 
incidence rate for melanoma has more than doubled. Melanoma is often curable 
if it is detected and treated in its early stages by surgical removal. However, in 
the late stages, melanoma tends to be very aggressive since it can spread 
(metastasis) to other parts of the body, such as lymph nodes, liver, lungs, or 
brain, and has poor response to chemo- and radiotherapy. At the present, there 
is no effective chemotherapy against invasive melanoma.   
 
 
Retinoids and melanoma skin cancer 
 
 Retinoids have been demonstrated to inhibit proliferation and induce 
differentiation of several mouse melanomas and a few human melanoma cell 
lines (Niles, 1985). These observations suggest the potential role of retinoids as 
a melanoma chemotherapeutic agent. However, many human melanoma skin 
cancers are resistant to retinoids (Rivers et al., 1989). The mechanisms involved 
in this resistance remain unclear. More research is focusing on the development 
of new synthetic retinoids that might overcome the resistance and reduce the 
side effects, such as retinoid dermatitis. Therefore, a better understanding of the 
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role of retinoids in the control of melanoma cells can offer new openings for 
prevention and treatment of melanoma. 
 
 
B16 mouse melanoma cell line 
 
Unlike many human melanoma cell lines that are resistant to the effects of 
RA, B16 cells are induced by RA to undergo growth arrest in the G1 phase of the 
cell cycle and to increase the production of melanin, an indicator of differentiation 
(Rogelj et al., 1984; Niles, 2003). Therefore, B16 mouse melanoma cell lines are 
frequently used as a melanoma model. B16 melanoma sublines (B16-F1, F5 and 
F10 corresponding to low, intermediate, and high metastatic potential) were 
established from C57BL/6 mouse melanoma (Fidler, 1975). These cell lines have 
higher metastatic potential than the parent cell line B16. The B16-F1 cell line has 
been used for all of my studies. This cell line forms tumors and lung metastasis 
when injected into animals. It also produces abundant amounts of melanin. 
 In mammals, melanin synthesis takes place in melanocytes after 
differentiation of the melanoblast, non-pigmented precursor (Le Douarin, 1982). 
Three melanocyte-specific enzymes including tyrosinase, TRP1 (tyrosinase-
related protein 1) and TRP2 (tyrosinase-related protein 2), whose expression is 
restricted in the melanocyte, are involved in the process that converts tyrosine to 
melanin pigments (Korner et al., 1982). In vivo, melanogenesis is stimulated by 
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α-melanocyte-stimulating hormone (α-MSH) which increases expression of 
tyrosinase (Levine et al., 1991). 
 
 
The effect of all-trans retinoic acid on cell growth and differentiation 
of B16 mouse melanoma cells 
 
 Retinoic acid, a biologically active metabolite of vitamin A, has been found 
to exert profound effects on cell growth and differentiation (DeLuca, 1991). 
Treatment of a variety of tumor cell lines with retinoids results in growth arrest, 
apoptosis, and/or differentiation (Lotan and Nicolson, 1977; Breitman et al., 1981; 
Oridate et al., 1995). In B16 mouse melanoma cells, all trans-retinoic acid inhibits 
both anchorage-dependent and -independent growth and stimulates melanin 
production (Niles et al., 1989). Previously, our laboratory reported that RA 
induced a six to eight fold increase in PKCα mRNA and protein (Rosenbaum and 
Niles, 1992). This increase in PKCα was accompanied by a three to four fold 
increase in activating protein-1 (AP-1) transcriptional activity (Desai et al., 1997). 
The action of RA on AP-1 is in contrast to many cell types, in which RA inhibits 
AP-1 transcriptional activity (Yang Yen et al., 1991; Salbert et al., 1993; Nagpal 
et al., 1995).  
    
 31
EXPERIMENTAL OBJECTIVE 
 
 This dissertation focused primarily on the effect of RA on AP-1 
transcriptional activity, with the aim of elucidating the role of the AP-1 
transcription complex in RA-dependent cell growth arrest and differentiation of 
B16 mouse melanoma cells. The first part of this dissertation has been focused 
on characterizing the stimulatory effect of RA on AP-1 transcriptional activity by 
establishing B16 clones which stably express an AP-1-luciferase reporter gene. I 
also investigated the function of increased AP-1 transcriptional activity in RA-
induced growth arrest and differentiation by establishing B16 clones which stably 
express A-Fos, a dominant-negative allele of the c-Fos gene (Olive et al., 1997). 
 The second part of this dissertation has been focused on the effect of RA 
on ATF2 phosphorylation in B16 mouse melanoma cells. During the course of 
studies on the mechanism by which RA increases AP-1 transcriptional activity, I 
found that B16 melanoma cells express a very high amount of ATF2, most of 
which is in the active (phosphorylated) form. The objective of the second part of 
my dissertation research was to determine the effect of RA on ATF2 expression 
and phosphorylation. Also I compared the expression and activation of ATF2 in 
B16 melanoma versus melan-a cells, a non-malignant immortalized melanocyte 
cell line derived from C57/BL mice. 
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CHAPTER 1 
 
Retinoic-Acid-Induced AP-1 Transcriptional Activity Regulates 
B16 Mouse Melanoma Growth Inhibition and Differentiation 
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INTRODUCTION 
 
 Vitamin A and its biologically active derivatives, collectively called 
retinoids, exert profound effects on embryogenesis (Gudas, 1994), cell growth 
and differentiation (Deluca LM, 1991), vision (Wald, 1968), and reproduction 
(Srikantia, 1975). Treatment of a variety of tumor cell lines with retinoids results 
in growth arrest, apoptosis, and/or differentiation (Lotan et al., 1977; Breitman et 
al., 1981; Oridate et al., 1995). In B16 mouse melanoma cells, all trans-retinoic 
acid (atRA) inhibits both anchorage-dependent and –independent growth and 
stimulates melanin production (Niles et al., 1989). Previously, our laboratory 
reported that RA induced a six to eightfold increase in PKCα mRNA and protein 
(Rosenbaum et al., 1992). This increase in PKCα was accompanied by a three to 
fourfold increase in activating protein-1 (AP-1) transcriptional activity (Desai et 
al., 1997). 
 The AP-1 transcription complex consists of homodimers and heterodimers 
of Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra1 and Fra2) (Tulchinsky, 
2000; Mechta-Grigoriou et al., 2001), or activating transcription factor (ATF2, 
ATF3/LRF1, B-ATF) bZip proteins (Hai et al., 2001). AP-1 activates the 
transcription of target genes by binding to specific consensus DNA sequences 
(TGAGTCA) found in a variety of promoters (David et al., 2001; Shaulian et al., 
2001). In many cell types RA inhibits AP-1 transcriptional activity (Yang-Yen et 
al., 1991; Salbert et al., 1993; Nagpal et al., 1995). The exact inhibitory 
mechanism of RA on AP-1 is still controversial. Several studies suggest that 
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activation of nuclear receptors (RAR/RXR) by RA results in a sequestration of co-
regulators, such as CBP/p300, which in turn reduces AP-1 transcriptional activity 
(Chakravarti et al., 1996; Torchia et al., 1997). 
 To further characterize the stimulatory effect of RA on AP-1 activity in 
mouse melanoma cells, we established B16 cell clones, which stably express an 
AP-1-luciferase reporter gene. We found that treatment of B16 mouse melanoma 
cells with RA induces a slow, but sustained elevation of AP-1 transcriptional 
activity.  
 To dissect the growth arrest and differentiation, we established clones of 
B16 which stably express A-fos, a dominant-negative version of the c-Fos gene 
(Olive et al., 1997). Expression of A-fos in B16 cells lowered control, phorbol 
dibutyrate- and RA-stimulated AP-1 transcriptional activity. We report here that 
inhibition of AP-1 activity through the expression of A-fos results in decreased 
sensitivity to RA-induced anchorage-dependent and –independent growth 
inhibition. The ability of RA to increase melanin synthesis was completely lost in 
clones where AP-1 activity was inhibited. Since expression of A-fos did not 
interfere with the ability of RA to increase RARβ or PKCα expression, these 
results cannot be explained by a non-specific inhibition of RAR transcription 
activation functions. The data suggest that RA-induction of AP-1 activity is either 
downstream of RARβ/PKCα stimulation or part of a parallel signaling pathway 
and that it plays an important role in mediating the phenotypic changes induced 
by RA.  
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MATERIALS AND METHODS 
 
 
Cells and Culture Conditions 
 
B16 mouse melanoma cells were grown in a humidified atmosphere of 5% 
CO2, 95% air at 37°C in Dulbecco’s Modified Eagle’s medium (DMEM). This 
medium contained 1g/L glucose and was supplemented with 10% heat-
inactivated bovine calf serum (Hyclone, Logan, UT), 50 U/ml penicillin G and 50 
µg/ml streptomycin sulfate. 
 
Retinoic acid, PDB, Bisindolylmaleimide, PD98059 and SB203580 
 
 All-trans-retinoic acid was obtained from Fluka Chemical Co (New York). 
All experiments involving the use of RA were conducted under yellow lights to 
prevent photo-oxidation of this retinoid. Fresh solutions of RA were prepared in 
DMSO for each experiment and then diluted to the final concentration in tissue 
culture media before adding to the cells.  
 Phorbol dibutyrate (PDB) was obtained from Sigma Chemical CO., St. 
Lois, MO and dissolved in DMSO. PDB stock solution (1 mM) was prepared and 
stored at -20°C. Cells were treated with 1µM PDB and assayed as described 
below.  
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 Bisindolylmaleimide (Boehringer Mannheim, Indianapolis, IN) is a specific 
and potent PKC inhibitor. Stock solution (2.5 mM) was prepared in DMSO and 
stored at -20°C, protected from light. A concentration of 2.5 µM was used for the 
selective analysis of PKC-mediated processes in the cellular system. 
 
Plasmid DNA Constructs 
 
 The AP-1-luciferase reporter plasmid was constructed by Dr. Sejal H. 
Desai (Desai and Niles, 1997). Four tandem repeats of the consensus AP-1 site, 
5’-TGAGTCA-3’ were inserted in the appropriate restriction sites of the pGL2 
vector upstream of an SV40 promoter followed by the gene encoding luciferase. 
CMV500 A-fos plasmid was kindly provided by Dr. Charles Vinson from the 
National Cancer Institute (NCI). This plasmid has a 5.7 kb fragment containing 
the A-fos gene, a neomycin resistance gene and has the FLAG epitope at the N-
terminus of the A-fos protein.  
 
Transient Transfection 
 
 Plasmid with or without the AP-1 consensus elements was transfected into 
early passage B16 cells via the Lipofectamine procedure (Gibco) together with 
plasmid containing SV40-β-gal to correct for transfection efficiency. B16 cells (7 
×105 cells/dish) were seeded into 100-mm tissue culture plates 1 day prior to 
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transfection. On the day of transfection, cells were refed with growth medium (no 
serum) 4 hours prior to the procedure. Transfections included 3 µg of the plasmid 
vector pGL2 with or without AP-1 response element and 1µg of pSV-β-
galactosidase (Promega, Madison, WI). Cells were incubated with the plasmid 
DNAs for 5 h before refeeding with growth medium (10% serum). Twenty-four 
hours after transfection, cells were washed twice with PBS and treated with 
corresponding concentrations of RA for 24 h, with 1µM PDB for the last 2 h 
before harvest. Cells were washed twice with PBS, harvested, and assayed for 
luciferase and β-galactosidase activity using the appropriate kits from Promega. 
Luciferase assays were evaluated in the linear range and values were 
normalized to β-galactosidase activity. All transfections were performed in 
triplicate dishes and the experiments were repeated three times. 
 
Stable Transfection 
 
 Early passage B16 cells were co-transfected with the AP-1-luciferase 
reporter plasmid and the pSVneo plasmid encoding resistance to G418 at a ratio 
of 9:1 (1 mg/ml). Transfection was accomplished by the lipofectamine procedure. 
G418-resistant clones were selected in Dulbecco’s Modified Eagle’s medium 
containing 1 mg/ml of G418 (BRL/GIBCO, Gaitherburg, MD). Resistant clones 
were screened by treatment with 1 µM PDB for 2 h followed by measurement of 
luciferase activity. B16 cells were also transfected with CMV500 A-fos as 
described above, except co-transfection with pSVneo was not necessary since 
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this plasmid contains the neo gene. Resistant clones were screened for the 
ability of PDB to increase AP-1 reporter gene activity in the transiently-
transfected G418-resistant clones described as above. 
 
Anchorage-Dependent Growth 
 
 Cells were seeded at 1 × 105 /100 mm tissue culture dish. After a 24 h 
attachment period, cells were treated with or without various concentrations of 
RA. Cells from triplicate dishes were harvested at various time points and cells 
were counted through the use of a hemacytometer. 
 
Anchorage-Independent Growth 
 
 A 3 ml bottom layer of 1% agarose in the appropriate growth medium and 
containing various concentrations of RA was dispensed into 60 mm tissue culture 
dishes. After the bottom layer solidified, a top layer (3 ml) containing 6,000 cells 
suspended in 0.3% agarose in the appropriate growth medium and at the 
appropriate concentration of RA was placed on top of the bottom layer. Lastly, a 
3 ml aliquot of growth medium containing the appropriate concentration of RA 
was added to the dishes. The liquid growth medium was replenished every 48 h. 
After 10 days of incubation, the number of colonies greater than 300 µm in 
diameter was counted. Each experimental and control group contained triplicate 
dishes. 
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Relative Melanin Content 
 
 Cells were seeded at appropriate densities such that densities of control 
and treated cultures would be equal at the time of harvest. Following a 24 h 
attachment period, cells were fed again with or without various concentrations of 
RA in growth medium. After 48 h of incubation, 1.5 ml aliquots of spent medium 
were taken and centrifuged at 12,000 × g for 10 min. The relative melanin 
content of supernatant fluids was determined by measuring A462nm. Cells were 
washed with cold PBS, then scraped into PBS followed by a 2,000 × g 
centrifugation. The cell pellets were dissolved in 1 ml of 1 N KOH and incubated 
at 80°C for 1 h. This hydrolysate was centrifuged at 12,000 × g for 10 min. The 
relative melanin concentration of the supernatants was determined by measuring 
the A462nm and the reading was normalized for the cell number. 
 
Western Blot Analysis for PKCα, ERK1/2, and JNK 
 
 Cells were seeded at 2 × 105/100 mm tissue culture dish. After a 24 h 
attachment period, they were again fed with growth medium containing RA or 
DMSO. Cells were harvested after 24 h or 48 h of incubation depending on the 
experiment and prepared for western blotting. 
 For PKCα western blot analysis, cells were washed with cold PBS and 
harvested in 250 µl of lysis buffer (10 mM Tris, PH 7.5, 1 mM EDTA, 1% glycerol, 
1 µg/ml leupeptin, 1 µg/ml pepstatin, 50 µg/ml aprotinin, 0.5 mM PMSF). Cells 
    
 40
were lysed on ice by three consecutive 10-sec sonications with a Tekmar® sonic 
disruptor at power setting 60. The total lysate was stored at -80 °C. 
 Protein concentration was determined by using the Pierce BCA protein 
assay kit. Protein (50 µg) was separated by SDS-PAGE with 10% separating and 
5% stacking gels.  The proteins were electrically transferred to a Hybond-C extra 
nitrocellulose membrane (Amersham, Chicago, IL). The membrane was 
incubated in blocking solution (Tris-buffered saline containing 0.2% Tween 20 
and 10% nonfat dry milk, TBST) for 1 h at room temperature. Blots were then 
incubated with a 1:1,000 dilution of monoclonal anti-PKCα antibody (Upstate 
Biotech, Saranac Lake, NY), polyclonal anti-JNK or polyclonal anti-phospho JNK, 
polyclonal anti-ERK1/2 or polyclonal anti-phospho ERK1/2 antibodies (each at 
1:1,000 dilution, Cell Signaling Technology, Beverly, MA) depending on the 
experiments for overnight at 4 °C. This solution was removed and the blot was 
washed several times in 1 × TBST followed by a 1 h incubation with 1:2,000 
dilution of rabbit anti-mouse horseradish peroxidase-conjugated secondary 
antibody (Cell Signaling Technology), and washed several times in 1 × TBST. 
Immuno-reactive bands were visualized by enhanced chemiluminescence 
(Amersham). 
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Detection of RARβ mRNA by RT-PCR 
 
 The RT-PCR kit purchased from Clontech (Menlo Park, CA) was used for 
these assays. One µg of RNA from control or RA-treated wildtype B16 cells, A-
fos clone 27, 71, and 12 cells was converted to cDNA using MMLV reverse 
transcriptase with oligo (dT) as primers. The 20 µl reaction contained 1 × reaction 
buffer from kit, 0.5 mM each of dATP, dTTP, dCTP and dGTP and 20 U of 
RNase inhibitor. PCR amplification of the cDNAs was performed using 50 µl 
reactions containing 1 × PCR buffer from kit, 0.2 mM each of dATP, dCTP, dTTP 
and dGTP plus 1 µl of Taq polymerase, 0.2 µM of each primer and 10 µl of the 
cDNA synthesized in the RT reaction. Primer sequences for RARβ were 5’-
TGCCAGGACAAGTCATCGGG-3’and 3’-GCTCCAACACCTCATTTGGTGACAT-
5’. All reactions were subjected to 25-30 PCR cycles. The typical reaction 
conditions were 1 min at 94 °C, 24-29 cycles at 94 °C for 30 sec, 68 ° C for 4 
min, then 5 min at 68 °C. The amplified cDNA products were separated by 
electrophoresis on 10% polyacrylamide gels, stained with ethidium bromide and 
visualized under UV light. 
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RESULTS 
 
Phorbol dibutyrate versus RA-induced AP-1 transcriptional activity 
 
 Early passage B16 cells were transfected with the reporter plasmid AP-1-
Luc as described in Materials and Methods. Fifty G418-resistant clones were 
screened for stable reporter gene activity and five consistently positive clones 
were obtained. These clones were determined to express the AP-1 reporter gene 
based on phorbol dibutyrate induction of luciferase activity. One of these clones, 
AP-1-Luc44 was used in the studies described below. The positive clone was 
treated for 48 h with or without various concentrations of RA. At the end of the 
treatment period all cells were harvested and assayed for luciferase activity. This 
experiment (Fig. 5A) revealed that RA induced a concentration-dependent 
increase in AP-1 transcriptional activity. This B16 clone was treated with or 
without 10 µM RA for different periods of time and assayed for luciferase activity. 
The results (Fig. 5B) showed that RA increased AP-1 transcriptional activity 
within 24 h of treatment, reached a maximum by 32 h and was maintained at this 
level for the duration of the experiment. In contrast to the effect of RA, phorbol 
dibutyrate increased AP-1 activity within 2 h of treatment, which then 
subsequently decreased to near control levels by 24 h of treatment (Fig. 5C). 
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Figure 5.  AP-1 transcriptional activity in RA versus PDB- treated 
clones of B16 melanoma cells stably expressing the AP-1-luciferase 
reporter gene 
         
 The AP-1-Luc44 clone of B16 cells, stably expressing the AP-1 reporter 
gene was treated with either vehicle (0.1% DMSO), all-trans retinoic acid or 
phorbol dibutyrate. At the end of the indicated incubation, cells were 
harvested and luciferase activity measured as described in Materials and 
Methods. Luciferase activity was normalized to the amount of total cellular 
protein. The data are presented as the mean ± SEM (error bars) of triplicate 
dishes for each treatment group. 
 
A. Cells were treated with the indicated concentrations of all-trans retinoic 
acid and harvested after 48 h of incubation. Statistical analysis used the 
Student t test, * correspond to Ps<0.05 compared with control. 
B. Cells were treated for the indicated time periods with 10 µM retinoic acid. 
C. Cells were treated for the indicated time periods with 1 µM phorbol 
dibutyrate. 
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Figure 5 
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Figure 5 
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Effect of bisindolylmaleimide on RA versus PDB-induced AP-1 
transcriptional activity 
 
     Since phorbol ester-activated PKC stimulates AP-1 activity (Bohmann et 
al., 1987), and RA-induced AP-1 transcriptional activity is accompanied by a 
large increase in PKCα mRNA and protein levels, I investigated the 
involvement of PKC enzyme activity in PDB versus RA-induced AP-1 
transcriptional activity. Previous studies found that PKC enzymatic activity 
from B16 cells was reduced 90% by 0.1 µM bisindolylmaleimide and was not 
detected at 1.0 µM inhibitor. AP-1-Luc44 clone of B16 cells were treated with 
10 µM RA, 1 µM PDB, 2.5 µM bisindolylmaleimide, or a combination of these 
compounds. Fig. 6A showed that inhibition of PKC enzymatic activity by 
bisindolymaleimide completely suppressed PDB induction of AP-1 
transcriptional activity. Fig. 6B showed that bisindolylmaleimide could not 
antagonize RA-induced AP-1 transcriptional activity. This experiment 
suggests that PDB does require PKC enzymatic activity to induce AP-1 
transcriptional activity. However, that is not the case for RA. 
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Figure 6. Effect of bisindolylmaleimide on PDB versus RA- 
induced AP-1 transcriptional activity 
 
 A clone of B16 melanoma cells stably expressing the AP-1-reporter gene, 
AP-1-Luc44, was treated with phorbol dibutyrate, all-trans-retinoic acid, 
bisindolylmaleimide, or a combination of these compounds. Cells were 
harvested and the luciferase activity was determined as described previously. 
Values were normalized to protein concentration. This experiment was 
performed in triplicate and the entire experiment was repeated three times. 
The data presented is the mean ± SEM (error bars). 
 
A. AP-1-Luc44 cells were treated with 1 µM PDB (2 h), 2.5 µM 
bisindolylmaleimide (24 h), or 2.5 µM bisindolylmaleimide (24 h) + 1 
µM PDB (2 h). 
B. AP-1-Luc44 cells were treated with 10 µM RA (24 h or 48 h), 2.5 µM 
bisindolylmaleimide (24 h or 48 h), or 2.5 µM bisindolylmaleimide + RA 
(24 h or 48 h). 
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Figure 6 
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Dominant-negative Fos Inhibits both Phorbol dibutyrate and RA-
induced AP-1 transcriptional activity 
 
 To investigate the functional significance of RA-induced AP-1 
transcriptional activity, we used a dominant-negative Fos construct. This 
construct consists of an acidic amphipathic protein sequence appended onto the 
N-terminus of the Fos leucine zipper. The acidic amphipathic protein sequence 
replaces the normal basic region critical for DNA binding (Olive et al., 1997). B16 
cells were transfected with either AP-1-luciferase reporter gene alone or co-
transfected with CMV500 A-fos plasmid. Cells were also co-transfected with a 
plasmid encoding β-galactosidase to correct for transfection efficiency. 
Transfected cells were treated with or without 10 µM RA; one group of 
transfected cells was treated with 1 µM PDB for the last 2 h or incubation. At the 
end of the incubation (a total of 48 h from the time of transfection), all cells were 
harvested and assayed for luciferase and β-galactosidase activity. A 2 h 
treatment with PDB and 24 h treatment with RA increased luciferase activity by 
5-fold and 3-fold in AP-1 reporter gene transfected cells, respectively. However, 
co-transfection of A-fos plasmid completely blocked both PDB and RA-induced 
AP-1 transcriptional activity compared with the DMSO treatment group. In 
addition, expression of A-fos in B16 cells significantly inhibited basal AP-1 
transcriptional activity (Fig. 7). These results suggest that A-Fos blocks AP-1 
activity in B16 cells. 
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Figure 7.  Effect of dominant-negative fos on PDB and RA- 
induced AP-1 transcriptional activity 
 
B16 cells were lipofectamine-transfected with the AP-1-reporter gene 
alone or co-transfected with CMV500 A-fos Plasmid, and plasmid encoding β-gal 
as described under Materials and Methods. Cells were treated with either vehicle 
(0.1% DMSO), 10 µM RA for 24 h, or 1 µM PDB for 2 h just prior to harvesting 
the cells. Forty-eight hours after transfection all groups were harvested and 
assayed for luciferase activity. Values were normalized for β-galactosidase 
activity. All transfections were performed in triplicate and the entire experiment 
was repeated three times. The data presented is the mean ± SEM (error bars) of 
triplicate dishes for each treatment group from a representative experiment.
 Statistical analysis used the Student t test. ** and *** correspond to Ps of 
<0.01 and <0.001 compared to cotransfection with A-Fos vector with the same 
reagents treatment, respectively.  
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Figure 7 
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Isolation of B16 clones expressing dominant-negative c-Fos 
  
Since RA induces a significant increase in AP-1 transcriptional activity, it is 
important to study the functional significance of AP-1 activity in RA-dependent 
cell growth inhibition and differentiation in B16 mouse melanoma cells. The 
approach we used was to isolate clones of B16 cells which stably express a 
plasmid containing a dominant-negative Fos and determine the role of AP-1 in 
B16 proliferation and differentiation. B16 cells were transfected with an A-Fos 
expression plasmid and G418-resistant clones selected as described in Material 
and Methods. Screening of clones by transient transfection showed that phorbol 
dibutyrate-induced AP-1 activity was inhibited in A-Fos clones 71 and 12, but not 
in 27 (Fig. 8A). A total of four clones were found which exhibited different levels 
of inhibition of phorbol dibutyrate-induced AP-1 activity. Clones 71 and 12 were 
used as positive A-Fos functional clones since they had the highest inhibitory 
activity, while 27 was used as a negative control for the experiments described 
below since only neomycin resistant gene but not A-Fos gene was expressed in 
this clone. We determined the effect of A-Fos on RA-stimulated AP-1 
transcriptional activity in these clones. The results (Fig. 8B) showed that RA-
stimulated AP-1 transcriptional activity was also inhibited in A-Fos clones 71 and 
12, but not in the negative clone 27. 
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Figure 8.  
 
A. Isolation of B16 clones expressing dominant-negative c-
Fos 
B16 cells were stably transfected with CMV500 plasmid containing 
A-fos cDNA driven by a CMV promoter. After treating cells with G418 for 
10 days, about 100 clones were selected. These clones were analyzed for 
A-Fos expression by transient transfection with an AP-1-luciferase 
reporter plasmid and an SV-β-gal plasmid (to correct for transfection 
efficiency). Transfected cells were treated with 1 µM PDB for 2 h prior to 
harvesting the cells. All cells were harvested and assayed for luciferase 
and β-galactosidase activity. The data, normalized for β-galactosidase 
expression, are presented as the mean ± SEM (error bars) of triplicate 
dishes for each group.  
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B. Effect of dominant-negative c-Fos on RA-induced AP-1 
transcriptional activity 
Wild type B16 cells and A-Fos clones 71, 12, and 27 were 
transiently transfected with an AP-1-luciferase reporter plasmid and an 
SV-β-gal plasmid (to correct for transfection efficiency). Transfected cells 
were treated with 10 µM RA for 24 h prior to harvesting the cells. All cells 
were harvested and assayed for luciferase and β-galactosidase activity. 
The data, normalized for β-galactosidase expression, are presented as the 
mean ± SEM (error bars) of triplicate dishes for each group. 
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Figure 8 
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Anchorage-dependent growth study in A-Fos clones 
 
 All-trans retinoic acid inhibits both anchorage-dependent and anchorage 
–independent growth in B16 mouse melanoma cells. This effect is accompanied 
by an increase in AP-1 transcriptional activity. I investigated the role of RA-
induced AP-1 activity in RA-dependent phenotypic changes in B16 cells by 
knocking out the AP-1 transcriptional activity using dominant-negative c-Fos. 
Wild type B16 cells and clones 27, 71, and 12 were treated with 10 µM RA for 
different periods of time and growth rates determined. We found that untreated 
cells from A-Fos positive clones 71 and 12 had growth rates similar to wt and A-
Fos negative clone 27. In wt B16 cells and A-Fos negative clone 27, RA inhibited 
cell growth by 70% after 72 h of treatment, while in A-Fos positive clones 71 and 
12 the decrease in cell growth at 72 h of treatment was only 40% (Fig. 9). We 
were unable to detect any obvious morphological differences between control 
and RA-treated A-Fos expressing clones or between these clones and wt B16 
cells. 
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Figure 9.  RA-induced inhibition of anchorage-dependent 
growth attenuated in A-Fos clones 
 
Wild type B16, A-Fos 27, 71, and 12 clones were seeded at 1 × 105 
cells/tissue culture dish. Following a 24 h of attachment period, cells were treated 
with 10 µM all-trans retinoic acid. At the indicated times cells were harvested and 
counted through the use of a hemacytometer. The data are presented as the 
mean ± SEM (error bars) of triplicate dishes. 
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Figure 9 
 
24                      48                        72
             
                    Time (hours)
ce
ll 
nu
m
be
r (
X1
05
)
0
5
10
15
20 control 
RA 
  24                      48                        72
                        Time (hours)
ce
ll 
nu
m
be
r (
X1
05
)
0
5
10
15
20
control 
RA 
  24                       48                       72
                      T im e (hours)
ce
ll 
nu
m
be
r (
X1
05
)
0
5
10
15
20 contro l 
R A  
24                       48                      72
                   Time (hours)
ce
ll 
nu
m
be
r (
X1
05
)
0
5
10
15
20
control 
RA 
Wt B16 
A-Fos#27 
A-Fos#71 
A-Fos#12 
    
 59
Anchorage-independent growth study in A-Fos clones 
 
 An important property of tumor cells is their ability to grow in an anchorage 
-independent fashion. Thus, I examined the concentration-dependent ability of 
RA to inhibit colony formation in soft agarose in A-Fos positive clones 12 and 71 
versus the A-Fos negative clone 27 and wt B16 cells. This phenotypic trait of B16 
cells is equisitively sensitive to inhibition by RA. Wt B16 cells and the A-Fos 
negative clone 27 had a 90% reduction in colony number relative to untreated 
cells at a concentration of 0.1 nM RA (Fig. 10). In contrast, the A-Fos positive 
clones 71 and 12 were relatively resistant to reduction of soft agarose growth by 
RA since approximately a 100-fold higher concentration of RA was required to 
achieve a 90% reduction in colony number (Fig. 10). 
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Figure 10.  RA-induced inhibition of anchorage-independent 
growth is attenuated in A-Fos clones 
 
Wild type B16 cells and A-Fos clones 27, 71, and 12 were seeded at 
6,000 cells/dish. Dishes contained a 1% base of Agarose in growth media and an 
overlay of 0.3% agarose containing cells plus growth media with or without 
corresponding concentration of RA. This layer was covered with 3 ml of growth 
media with or without corresponding concentration of RA. After 10 days of 
incubation (changing growth media in the top layer every 2 days), colonies equal 
to or greater than 300 µm in diameter were counted. The data are presented as 
the mean ± SEM (error bars) of triplicate dishes. 
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Figure 10 
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Effect of A-fos expression on B16 differentiation 
 
 As a function of its induction of differentiation, RA stimulates melanin 
production in B16 mouse melanoma cells. We determined whether AP-1 
transcriptional activity was involved in this response. The results showed that 10 
µM all-trans retinoic acid increased melanin levels to almost the same extent in 
wt B16 cells and the A-Fos negative clone 27 (Fig. 11). However, RA treatment 
of A-Fos positive clones 71 and 12 did not result in any increase in melanin 
production (Fig. 11). 
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Figure 11.  Expression of A-fos blocks RA-induced melanin 
production 
 
Wild type B16 cells and A-Fos clones 27, 71, and 12 were treated with 10 
µM all-trans retinoic acid for 48 h. Cells were then harvested and lysed in 1 N 
KOH at 80 °C for 1 h. The hydrolysate was centrifuged at 12,000 × g and the 
absorbance of the supernatant measured at 462 nm (relative melanin corrected 
for cell number). The data are presented as the mean ± SEM from triplicate 
dishes of control and treated cells. 
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Figure 11 
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Effect of A-fos expression on the RA-induced RARβ expression 
 
 The RAR nuclear receptors are members of a large group of ligand-
dependent transcription factors. Because these receptors share a common co-
activator with the AP-1 transcription complex, i.e., CBP/P300, it is possible that 
overexpression of A-fos might sequester CBP/P300 and prevent normal RA-RAR 
signaling. B16 cells constitutively express RARα and γ, but lack expression of 
RARβ. Administration of RA results in a rapid up-regulation of RARβ expression 
(Hai and Hartman, 2001). Therefore, I determined the ability of RA to induce 
RARβ mRNA in both wt B16 cells and in the negative and positive A-Fos clones. 
RT-PCR was used as a qualitative measure of the induction of RARβ by RA. The 
results (Fig. 12) indicate that RARβ was induced by RA in all the cells 
irrespective of whether or not A-Fos was expressed. 
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Figure 12.  A-fos expression does not inhibit RA-induced RARβ 
expression 
  
Wild type B16 cells and A-Fos clones 12, 27, and 71 were treated with 10 
µM all-trans retinoic acid for 4 h. One µg of RNA from control or treated cells was 
converted to cDNA using MMLV reverse transcriptase and the RARβ cDNA 
amplified using specific primers (see Materials and Methods). The products were 
separated on 10% polyacrylamide gels, stained with ethidium bromide, visualized 
under UV light and photographed. The data shown are from a representative 
experiment which was replicated three additional times with similar results.  
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Figure 12 
 
 
RARβ
C:   cells treated with DMSO for 4 h 
 
RA: cells treated with 10% RA for 4 h 
    
 68
Effect of A-fos expression on the RA-induced PKCα expression 
 
 Our previous research found that RA treatment of B16 cells induced a 
significant increase in PKCα mRNA and protein (Rosenbaum et al., 1992). I 
tested whether this induction was altered in B16 clones expressing A-fos. 
Positive clones 71 and 12, as well as negative clone 27 and wt B16 cells were 
treated with 10 µM RA for 24 h. The amount of PKCα protein in control and 
treated cells was determined by western blotting. The results (Fig. 13) indicate 
that the relative induction of PKCα protein by RA was roughly the same in all 
clones. 
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Figure 13.  RA-induced increase in PKCα protein is independent  
of AP-1 transcriptional activity 
  
Wild type and A-Fos clones 27, 71, and 12 were treated with 10 µM all-
trans retinoic acid for 24 h. Cells were harvested and 50 µg of protein from each 
group was analyzed by western blotting using monoclonal PKCα antibody as 
described in Materials and Methods. The autoradiogram (top) was scanned using 
a Molecular Dynamics densitometer and after correcting for the amount of 
GAPDH protein, the relative amount of PKCα in each sample was determined 
(bottom). The data shown are from a representative experiment which was 
replicated three additional times with similar results. 
    
 70
Figure 13 
 
            w t            A -Fos#71       A -Fos#27       A -Fos#12
PK
C
α p
ro
te
in
 le
ve
l/G
A
PD
H
0
1
2
3
4
5
control
RA
    
 71
Signaling pathway involved in RA-induction of AP-1 transcriptional 
activity 
 
 The purpose of this study was to determine the molecular mechanism 
involved in RA-induced AP-1 transcriptional activity. Since MAP kinase signaling 
pathways have been implicated in stimulation of AP-1 (Huang et al., 1998), I 
investigated their potential role in RA induction of AP-1 by using the MEK 
selective inhibitor PD98059 and the P38 MAPK selective inhibitor SB203580. 
Surprisingly, the MEK inhibitor, PD98059 by itself stimulated AP-1 activity by 3-
fold to almost the same as did RA (Fig. 14A). Combined treatment of B16 cells 
with PD98059 and RA did not result in an additive stimulation of AP-1 activity, 
suggesting some potential commonality in how these two compounds stimulate 
AP-1. The P38 MAPK inhibitor, SB203580 had little or no effect on AP-1 activity 
either by itself or combined with RA. Since we did not have access to a selective 
JNK MAPK inhibitor, we directly examined its state of activation in control and 
RA-treated cells through the use of total and phospho-specific JNK antibodies. 
Figure 14B showed that there is no change in either total or phospho-specific 
(activated) JNK in control versus 24 h RA-treated B16 cells, a time at which RA 
increases AP-1 transcriptional activity. 
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Figure 14. 
 
A. Effect of inhibition of MAP kinases on AP-1 transcriptional 
activity 
 
Clones of B16 mouse melanoma cells stably expressing the AP-1 
-luciferase reporter gene were treated with 10 µM PD98059 (24 h), 10 µM 
RA (24 h), 10 µM SB203580 (24 h), PD98059 + RA or SB203580 + RA. At 
the end of the incubation, cells were harvested and luciferase activity 
measured as described in Materials and Methods and values were 
normalized to protein concentration. This experiment was performed in 
triplicate and the entire experiment was repeated three times. The data  
are presented as the mean ± SEM (error bars). 
 
B. The effect of RA on activation (phosphorylation) of JNK 
 
B16 cells were treated with 10 µM RA for the indicated times. Cells 
were then harvested, extracted and protein from each sample examined 
for total and phospho-specific JNK by western blotting as described in 
Materials and Methods. The results presented are from a representative 
experiment, all experiments were repeated three times with similar results. 
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DISCUSSION 
 
In the first part of the study, I further characterized the RA-induced 
increase in AP-1 transcriptional activity in B16 mouse melanoma cells and 
contrasted this increase with that induced by phorbol dibutyrate. I also examined 
the role of this increase in AP-1 transcriptional activity in the pathways by which 
RA induces growth arrest and differentiation of B16 melanoma cells. 
RA induced a concentration-dependent increase in AP-1 transcriptional 
activity that had not reached saturation at the highest concentration tested (10 
µM). This concentration-dependent response is similar to the effect of RA on 
inhibition of anchorage-dependent growth in B16 cells (Niles et al., 1991). 
Although the highest concentration, 10 µM is supraphysiological, B16 cells grown 
in monolayer culture are less susceptible to a variety of drugs. For example, a 
concentration of 1-1.5 mg/ml of G418 is required to kill B16 cells not expressing 
the neomycin resistance gene, whereas most other cell lines only require 400-
600 µg/ml to achieve the same result. In contrast, B16 cells grown in an 
anchorage-independent fashion are very sensitive to RA. Using a clone of B16 
stably expressing the AP-1 luciferase reporter gene, we found that RA-induction 
of AP-1 activity was a slow response, which did not reach its maximum until 48 h 
of treatment. This kinetic response is in marked contrast to treatment with 
phorbol dibutyrate. This phorbol ester induced a rapid increase in AP-1 activity, 
which peaked at about 2-4 h and then returned almost to baseline levels by 24h 
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of treatment. These disparate results suggest that the mechanisms by which RA 
and phorbol dibutyrate increase AP-1 activity are likely quite different. 
In order to gain some insight into the role of the RA-induced increase in 
AP-1 transcriptional activity in the subsequent growth arrest and differentiation of 
B16 melanoma cells, I used a dominant-negative c-Fos, termed A-Fos. The A-
Fos protein can form heterodimers, but cannot bind to DNA. The diagram of A-
Fos is shown in Figure 15.  
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Figure 15. Diagram of dominant-negative c-Fos (A-Fos) 
 
To investigate the function of the AP-1 transciption complex in cellular 
processes that are regulated by RA in B16 cells, I used a dominant-negative c-
Fos, termed A-Fos, which was designed by Dr. Charles Vinson’s lab (Olive et al., 
1997) to inhibit the sequence-specific DNA binding of the AP-1 complex. This 
construct consists of an amphipathic acidic protein sequence (LEQRAEE 
LARENEE LEKEAEE LEQELAE LE) appended onto the N-terminus of the Fos 
leucine zipper, replacing the normal basic region required for DNA binding. 
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Figure 15 
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 Expression of A-Fos in B16 cells significantly inhibited basal, phorbol 
dibutyrate-stimulated and RA-stimulated AP-1 transcriptional activity. 
Interestingly, clones of B16 stably expressing A-Fos had growth rates similar to 
wild-type cells and a clone of B16 not expressing functional A-Fos. AP-1 
transcriptional activity is rapidly induced by a variety of mitogens and is thought 
to mediate part of the signaling pathway that stimulates cell proliferation 
(Boulikas, 1995; Wisdom, 1999; van Dam et al., 2001). Since inhibition of AP-1 
activity did not substantially decrease proliferation in the A-Fos clones, it 
suggests that these cells have redundant pathways that mediate growth factor 
signaling. 
Inhibition of anchorage-dependent and –independent growth in A-Fos 
expressing clones by RA was attenuated compared to wild-type and a clone not 
expressing functional A-Fos. These data suggest that RA-induced AP-1 
transcriptional activity is involved in mediating at least part of the effect of RA on 
these two different modes of B16 proliferation. Growth of B16 cells in agarose is 
equisitively sensitive to RA, with 0.1 nM RA reducing colony formation by 90%. 
The reason why B16 cells grown under these conditions are very sensitive, while 
those grown in an anchorage-dependent fashion are relatively resistant to the 
growth inhibitory effects of RA is not known. 
A marker of RA-induced differentiation of B16 melanoma cells is an 
increase in melanin production. In the A-Fos expressing clones, basal melanin 
production was not altered compared to wild-type cells, but the ability of RA to 
stimulate melanin synthesis was lost. The role of AP-1 in regulating 
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melanogenesis has not been extensively studied. Englaro et al. (1995, 1999) 
found that cAMP-elevating agents, known to stimulate melanogenesis, increased 
p44 MAPK activity, which in turn activated the transcription factor AP-1. It was 
hypothesized that AP-1 stimulated tyrosinase gene expression, the rate-limiting 
enzyme in melanin synthesis, through an AP-1 response element present in the 
mouse tyrosinase promoter. The mechanism by which RA increases melanin 
production is not known, but the results of our present study suggest that RA-
induced AP-1 transcriptional activity is required. 
Since RAR and AP-1 share a common co-activator, i.e., CBP/p300 
(Torchia et al., 1997), one explanation for our results could be that 
overexpression of A-Fos sequestered the limiting amount of CBP/p300 available 
in B16 cells and therefore, prevented the full transcription activation function of 
the RAR. However, our data show that, similar to wild-type and non-expressing 
A-Fos clones, RA induced RARβ and PKCα expression in clones expressing 
functional A-Fos. Thus, the RARs are fully functional in these clones, ruling out 
“squelching” of these receptors as an explanation of our results. These findings 
also suggest that RA-induced increase in AP-1 transcriptional activity is either 
downstream of the induction of RARβ and PKCα, or they are on parallel signal 
transduction pathways. 
There have been several studies showing that one or more MAP kinase 
pathways regulate induction of AP-1 transcriptional activity (Huang et al., 1998; 
Watts et al., 1998; Kletsas et al., 2002). Therefore, we were somewhat surprised 
that inhibition of MEK, and thus the Erk1/2 MAP kinase pathway, stimulated AP-1 
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activity in B16 melanoma cells. Since the combination of RA and PD98059 and 
RA did not result in an additive increase in AP-1 transcriptional activity, there 
may be some overlap in the pathway (i.e., Erk1/2 MAP kinase) by which 
PD98059 and RA stimulate AP-1 transcriptional activity. We are currently 
examining the possibility that RA interferes with signaling mediated by the Ras, 
Raf, MEK, Erk1/2 MAP kinase resulting in stimulation of AP-1 transcriptional 
activity. 
The AP-1 transcription complex is a homo- or heterodimer, composed of 
two bZIP proteins, commonly a Fos family member and a Jun family member. As 
an immediate early transcription factor, AP-1 has been shown to play an 
important role in the initiation of cell proliferation (Boulikas, 1995; Wisdom, 1999; 
van Dam et al., 2001). Many studies have shown that RA inhibits AP-1 
transcriptional activity (Yang-Yen et al., 1991; Salbert et al., 1993; Nagpal et al., 
1995). These findings are in marked contrast to our observation that RA 
increases AP-1 transcriptional activity in B16 cells. However, RA induces AP-1 
activity in several other cell lines such as F9 teratocarcinoma (Muller et al., 1984; 
Kindregan et al., 1994) and neuroblastoma (deGroot et al., 1991). Additionally, 
there is some evidence that increased AP-1 activity is important in human 
melanoma differentiation (Kang et al., 1998). A specific human melanoma 
differentiation associated (mda) gene, mda-7, exhibits reduced expression as a 
function of melanoma progression from melanocyte to metastatic melanoma. 
Treatment of metastatic human melanoma cells with inducers of differentiation 
resulted in increased expression of mda-7 mRNA and protein. The promoter 
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region of this gene contains sites for AP-1 binding and ectopic expression of AP-
1 enhanced the expression of the mda-7 promoter in human melanoma cells 
(Madireddi et al., 2000). In B16 cells, RA does not increase the expression of any 
of the Fos or Jun family members, nor does it increase the binding activity of the 
AP-1 complex (Desai et al., 1997). PKC enzyme activity is not required for the 
RA-induced AP-1 transcriptional activity, since bisindolylmaleimide, a fairly 
specific PKC inhibitor did not block the response (Desai et al., 1997; and this 
present study). Also, we have previously shown that phorbol dibutyrate-induced 
AP-1 activity in B16 cells is associated with a rapid increase in c-Fos mRNA and 
protein expression and that the induction of c-Fos is antagonized by RA (Desai et 
al., 1997). Thus, our working hypothesis is that RA antagonizes the type of AP-1 
activity stimulated by phorbol esters (and perhaps other types of mitogenic 
stimuli?) and induces a different type of AP-1 activity that is required for growth 
arrest and differentiation.  
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INTRODUCTION TO DISSERTATION PART II 
 
 From the first part of my dissertation research, I produced evidence that 
RA-induced AP-1 transcriptional activity plays a key role in the growth inhibition 
and differentiation mediated by this retinoid in B16 mouse melanoma cells. 
However, the molecular mechanism by which RA increases AP-1 transcriptional 
activity remains unclear. In B16 cells, RA does not increase the expression of 
any of the Fos or Jun family members. Therefore, ATF2, another member of the 
AP-1 transcription complex, became the target of the second part of my 
dissertation research. Specifically, the aims were: 
1. to measure the expression level of ATF2 protein in control and RA-treated 
B16 melanoma cells and non-malignant melan-a mouse melanocytes 
2. to examine the effect of RA on ATF2 activation (phosphorylation) 
3. to study the signaling pathway involved in RA-dependent inhibition in 
ATF2 phosphorylation 
4. to determine whether RA sensitizes B16 cells to chemotherapeutic agents 
via its ability to decrease the phosphorylation (activation) of ATF2 
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CHAPTER 2 
 
Retinoic Acid Inhibits ATF2 Phosphorylation in B16 Mouse 
Melanoma Cells 
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INTRODUCTION 
 
The incidence of cutaneous melanoma has been rapidly increasing in the 
past few years. In the early stages, melanoma is curable in most cases by 
surgery, but once the metastases develop, the median survival for patients is 
only 8.5 months.  Treatment for patients with metastatic melanoma has been 
problematic because of its poor response to chemo- and radiotherapy. Retinoids 
have been shown to inhibit proliferation and induce differentiation of several 
mouse melanomas and a few human melanoma cell lines (Niles, 1985).  In B16 
mouse melanoma cells, all trans-retinoic acid inhibits both anchorage-dependent 
and –independent growth and stimulates melanin production (Niles et al., 1989).  
Previously, our laboratory reported that RA induced a three to fourfold increase in 
activating protein-1 (AP-1) transcriptional activity (Desai et al., 1997).  This RA-
induced AP-1 transcriptional activity plays an important role in the biological 
changes induced by this retinoid in B16 melanoma cells because blocking AP-1 
transcriptional activity by dominant negative c-Fos significantly decreases the 
sensitivity to RA-dependent cell growth arrest and differentiation (Huang et al., 
2002).  
 Activating transcription factor 2 (ATF2) is a member of the ATF/CREB 
family of basic region leucine zipper (bZIP) proteins.  Jun and Fos bZIP families, 
together with ATF2 constitute the AP-1 transcription factor family.  AP-1 
transcription factors mediate gene regulation in response to specific growth 
factors, cytokines, tumor promoters, carcinogens and oncoproteins.  Based on 
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these findings, AP-1 has been considered a key regulator of various complex 
biological processes, such as cell proliferation, transformation, differentiation, 
and apoptosis (Angel et al., 2001).  AP-1 activates the transcription of target 
genes by binding to specific consensus DNA sequences.  Jun:Jun and Jun:Fos 
dimers preferentially bind to the TRE (TGACTCA); whereas Jun:ATF2 
heterodimers or ATF2 homodimers prefer to bind to CRE (TGACGTCA).  ATF2 
has been implicated in modulating melanoma proliferation (Recio et al., 2002) 
and resistance to treatment (Yang et al., 1996; Ronai et al., 1998).  Under 
nonstressed conditions, ATF2 is transcriptionally inactive because of its 
intramolecular inhibition, in which the ATF2 activation domain and bZIP domain 
specifically bind to each other (Li et al., 1996).  ATF2 is known to acquire its 
transcriptional activity upon phosphorylation by MAP kinases, including JNK and 
p38 (Gupta et al., 1995).  Phosphorylation at two threonine sites within the N-
terminal activation domain leads to ATF2 conformational changes, which 
releases the intramolecular inhibition. Bhoumik et al., 2001 reported that blocking 
ATF2 transcriptional activity by using an ATF2-derived peptide could sensitize 
melanoma cells to apoptosis induced by chemotherapeutic drugs, or inhibitors of 
stress kinases.  
 In studying the molecular mechanism involved in RA-induced AP-1 
transcriptional activity, we found that RA did not increase the expression of any 
of the Fos or Jun family members.  Therefore we investigated whether RA 
altered the expression of the AP-1 family member ATF2.  We demonstrate that 
ATF2 is expressed at a much higher level in B16 melanoma cells when 
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compared to an immortalized but non-malignant mouse melanocyte cell line.  A 
much higher percentage of the ATF2 protein is in the phosphorylated form 
(active) in B16 cells, compared with the non-malignant cells.  Forty-eight hours of 
RA treatment reduces ATF2 phosphorylation by inhibiting p38 MAP kinase 
activation.  Since ATF2 has been implicated in melanoma resistance to 
chemotherapy, we determined whether RA might sensitize B16 cells to the 
chemotherapeutic agent taxol.  Pretreatment with RA for 48 h dramatically 
lowered the inhibitory concentration of taxol, a tubulin-polymerizing agent, 
required to induce a decrease in B16 cell numbers.  
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MATERIALS AND METHODS 
 
 
Cells and Culture Conditions 
 
B16 mouse melanoma cells were grown in a humidified atmosphere of 5% 
CO2, 95% air at 37°C in Dulbecco’s Modified Eagle’s medium (DMEM). This 
medium contained 1g/L glucose and was supplemented with 10% heat-
inactivated bovine calf serum (Hyclone, Logan, UT), 50 U/ml penicillin G and 50 
µg/ml streptomycin sulfate. 
Immortal mouse melanocytes, the Melan-a cell line, was provided by Dr. 
Dorothy C Bennett, St George’s Hospital Medical School, UK. Melan-a cells were 
grown in a humidified atmosphere of 10% CO2, 90% air at 37°C in RPMI 1640 
culture medium. This medium contained 2 mM L-glutamine and was 
supplemented with 5% fetal calf serum, 200 nM TPA (tetradecanoyl phorbol 
acetate), 100 U/ml penicillin G and 100 µg/ml streptomycin sulfate. TPA was 
added to medium on the day of use because of its light sensitivity, then the bottle 
of medium was covered by aluminum foil.  
 
Retinoic acid, SB203580, and Taxol 
 
 All-trans-Retinoic acid was obtained from Fluka Chemical Co (New York). 
All experiments involving the use of RA were conducted under yellow lights to 
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prevent photo-oxidation of this retinoid. Fresh solutions of RA were prepared in 
DMSO for each experiment and then diluted to the final concentration in tissue 
culture media before adding to the cells.  
 SB203580 was obtained from Biomol Research Laboratories, Inc. 
(Plymouth Meeting, PA). A concentrated stock solution of SB203580 (10 mM) 
was prepared in DMSO and then stored at -20°C. This stock solution was diluted 
to the desired final concentration in tissue culture medium before adding to the 
cells. 
 Paclitaxel (taxol) was obtained from LC Labs (Wobum, MA). A 
concentrated stock solution of taxol (10 µM) was prepared in DMSO and then 
stored at -20°C in the dark. This stock solution was diluted to the desired final 
concentration in tissue culture medium before adding to the cells.  
  
Plasmid DNA Constructs 
 
 CRE-Luciferase reporter plasmid was from PathDetect® in vivo signal 
transduction pathway cis-reporting systems, Stratagene (La Jolla, CA). This 
vector contains the luciferase reporter gene driven by base promoter element 
(TATA box) joined to tandem repeats of CRE (TGACGTCA) binding element.  
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Transient Transfection 
 
 Plasmid with or without the CRE consensus elements was transfected into 
early passage B16 cells via the Lipofectamine procedure (Gibco) together with 
plasmid containing SV40-β-gal to correct for transfection efficiency. B16 cells 
were seeded (7 ×105 cells/dish) into 100-mm tissue culture plates 1 day prior to 
transfection. On the day of transfection, cells were refed with growth medium 4 
hours prior to the procedure. Transfections included 3 µg of the plasmid vector 
pGL2 with or without CRE response element and 1 µg of pSV-β-galactosidase 
(Promega, Madison, WI). Cells were incubated with the plasmid DNAs for 5 h 
before refeeding the complete medium. Twenty-four hours after transfection, 
cells were washed twice with PBS and treated with corresponding concentrations 
of RA for 24 h before harvest. Cells were washed twice with PBS, harvested, and 
assayed for luciferase and β-galatosidase activity using the appropriate kits from 
Promega. Luciferase assays were evaluated in the linear range and values were 
normalized to β-galatosidase activity. All transfections were performed in 
triplicate dishes and the experiments were repeated three times. 
 
Crystal Violet Assay 
 
 A colorimetric assay employing crystal violet was used to test for 
therapeutic drug (taxol) sensitivity. This assay is based on the staining attached 
cells (viable cells) with crystal violet dye in each well (Wosikowski et al., 1993). 
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After the treatment period, triplicate wells with various concentrations of taxol and 
a control group were fixed with methanol:acetic acid (3:1) for 1 h at room 
temperature. The fixed cells were washed with 80% methanol and stained with 
crystal violet (0.5%) for 1 h. Excess dye was removed by washing the wells with 
distilled water. Wells were air-dried and the dye was eluted with 500 µl of 10% 
acetic acid. Two hundred µl of eluted dye from each well were transferred to 96-
well plates and absorbance was measured at 570 nm with a kinetic microplate 
reader (Molecular Devices Corporation, Sunnyvale, CA). Absorbance values 
from the taxol-treated group were compared to values from the control group. 
 
Western Blot Analysis for ATF2, ERK1/2, JNK, and p38 
 
 Cells were seeded at 2 × 105/100 mm tissue culture dish. After a 24 h 
attachment period, they were again fed with growth medium containing RA or 
DMSO. Cells were harvested after 24 h or 48 h of incubation depending on the 
experiment and prepared for western blotting. 
 For total ATF2 protein analysis, B16 cells and Melan-a cells were washed 
two times with PBS, harvested to prepare cytoplasmic and nuclear extracts by 
Pierce NE-PERTM nuclear and cytoplasmic extraction reagents.   
 For other western blot analysis, cells were washed with cold PBS and 
harvested in 250 µl of lysis buffer (10 mM Tris, PH 7.5, 1 mM EDTA, 1% glycerol, 
1 µg/ml leupeptin, 1 µg/ml pepstatin, 50 µg/ml aprotinin, 0.5 mM PMSF). Cells 
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were lysed on ice by three consecutive 10-sec sonications with a Tekmar® sonic 
disruptor at power setting 60. The total lysate was stored at -80 °C. 
 Protein concentration was determined by using the Pierce BCA protein 
assay kit. Protein (50 µg) was separated by SDS-PAGE with 10% separating and 
5% stacking gels.  The proteins were electrically transferred to a Hybond-C extra 
nitrocellulose membrane (Amersham, Chicago, IL). The membrane was 
incubated in blocking solution (Tris-buffered saline containing 0.2% Tween 20 
and 10% nonfat dry milk, TBST) for 1 h at room temperature. Blots were then 
incubated overnight at 4°C with a 1:1,000 dilution of polyclonal anti-JNK or 
polyclonal anti-phospho JNK, polyclonal anti-ERK1/2 or polyclonal anti-phospho 
ERK1/2, polyclonal anti-p38 or polyclonal anti-phospho p38, or polyclonal anti-
phospho-ATF2 antibodies (each at 1:1,000 dilution, Cell Signaling Technology, 
Beverly, MA) depending on the experiments. This solution was removed and the 
blot was washed several times in 1 × TBST followed by a 1 h incubation with 
1:2,000 dilution of rabbit anti-mouse horseradish peroxidase-conjugated 
secondary antibody (Cell Signaling Technology), washed several times in 1 × 
TBST. Immunoreactive bands were visualized by use of the ECL kit from 
Amersham. 
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Protein Phosphatase-1 (PP1) Treatment for ATF2 Protein 
 
 Protein phosphatase-1 (PP1) is a Mn2+-dependent protein phosphatase 
with activity towards phosphoserine/threonine residues. Each 50 µl reaction 
contained: 25 µg nuclear protein isolated from B16 cells, 1 × PP1 buffer, 1mM 
MnCl2, and 2 units of PP1. Samples were incubated at 30°C for various times 
and the reaction was stopped by the addition of 5 µl of 10 × sample buffer 
followed by boiling of the samples. Proteins were separated by SDS-PAGE with 
10% separating and 5% stacking gels. The proteins were electrically transferred 
to a Hybond-C extra nitrocellulose membrane. Blots were then incubated 
overnight at 4°C with 1:1,000 dilution of polyclonal anti-phospho-ATF2 antibody 
and 1:5,000 dilution of monoclonal anti-GAPDH antibody, respectively.   
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RESULTS 
 
Expression and activation of ATF2 protein in malignant mouse 
melanoma cells versus normal mouse melanocytes 
 
 Previous work from our laboratory has shown that RA induces AP-1 
transcriptional activity in B16 mouse melanoma cells. However, RA does not 
increase the expression of any of the Fos or Jun family members. In the course 
of this work we have studied the role that ATF2 protein plays in this cell line as 
part of various AP-1 complexes. 
 Initially, we compared the expression levels of total ATF2 protein between 
B16 and melan-a cells. Both cell lines are derived from the same genetic strain of 
mice, ie C57BL/6. B16 is a metastatic mouse melanoma cell line; Melan-a is an 
immortalized, but not transformed mouse melanocyte cell line. Only trace 
amounts of ATF2 were detected in the cytoplasm, with the vast majority of ATF2 
protein in the nuclear fraction. Higher levels of ATF2 protein were detected in 
malignant melanoma cells, compared to non-malignant mouse melanocytes (Fig. 
16A). 
 ATF2 was detected as multiple bands of approximately 70 kDa in nuclear 
extracts from B16 and Melan-a cells. The higher MW band was more prominent 
in the B16 nuclear extracts than that in the Melan-a cell nuclear extracts. We 
suspected that the higher MW band was phosphorylated ATF2. To demonstrate 
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that ATF2 was phosphorylated, the nuclear extracts from B16 cells were 
incubated with protein phosphatase-1A (PP1A) for different periods of time, and 
then ATF2 protein detected using an antibody specific for phospho-ATF2.  This 
experiment (Fig. 16B) showed that detected phospho-ATF2 was lost, even after 
a short incubation period (3 min). Therefore we concluded that the higher MW 
form of ATF2 is the result of phosphorylation. 
 Stimulation of ATF2 transcriptional activity requires its phosphorylation by 
the MAP kinases P38 or JNK. We examined ATF2 phosphorylation as an 
indicator of its activation in malignant melanoma cells, compared to non-
malignant mouse melanocytes through the use of total and phospho-specific 
ATF2 antibodies. Fig. 16C shows that over 70% of total ATF2 protein in 
malignant mouse melanoma cells is phosphorylated (activated); while only 16% 
of total ATF2 protein in non-malignant mouse melanocyte is phosphorylated. 
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Figure 16. 
 
A. Total ATF2 expression levels in B16 cells versus Melan-a 
cells 
 
The morphological pictures of B16 cells and Melan-a cells were 
taken by phase contrast diaphot (top left panel). B16 cells and Melan-a 
cells were harvested at 80% confluence, and cytoplasmic and nuclear 
protein were isolated using Pierce NE-PERTM nuclear and cytoplasmic 
extraction reagents described in Materials and Methods. 10 µg of 
cytoplasmic and nuclear proteins from both cell lines were analyzed by 
western blotting using polyclonal ATF2 antibody. The autoradiogram (top 
right panel) was scanned using a Molecular Dynamics densitometer and 
after correcting for the amount of β-actin, the relative amount of total ATF2 
in each sample was determined (bottom). The data shown are from a 
representative experiment which was replicated three additional times with 
similar results. 
 
B. ATF2 is a phospho-protein 
 
Nuclear extracts prepared from B16 cells were treated with 2 units 
of PP1 at 37°C. The reaction was stopped by the addition of sample buffer 
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at the indicated incubation times. The samples were boiled, then blotted 
using phospho-ATF2 antibody. GAPDH was used as an internal control. 
The data are representative of three individual experiments with similar 
results. 
 
C. Quantitation of ATF2 phosphorylation in B16 cells versus 
Melan-a cells 
 
Twenty µg of cellular extracts from B16 cells and 40 µg of cellular 
extracts from Melan-a cells were analyzed by western blotting using anti-
ATF2 polyclonal antibody and anti-phospho-ATF2 polyclonal antibody, as 
described in Materials and Methods. The autoradiogram (top) was 
scanned using a Molecular Dynamics densitometer and after correcting for 
the amount of total ATF2 protein, the relative amount of phospho-ATF2 
protein in both cell lines was determined (bottom). The data shown are 
from a representative experiment which was replicated three additional 
times with similar results. 
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Figure 16 
 
 
 
 
 
B16 cells                 
Melan-a cells  
B16 cells Melan-a cells 
A 
     B16 cells                   Melan-a cellsR
el
at
iv
e 
de
ns
ity
 o
f t
ot
al
 A
TF
2 
pr
ot
ei
n 
in
 n
uc
le
us
0.0
0.2
0.4
0.6
0.8
1.0
1.2
    
 98
Figure 16 
 
 
 
 
 
 
 
 
 
 
B 
    
 99
Figure 16 
 
   
 
 
 
 
 
         B16 cells                      Melan-a cellsr
el
at
iv
e 
%
 o
f t
-A
TF
2 
w
hi
ch
 is
 p
ho
sp
ho
ry
la
te
d
0
20
40
60
80
C 
    
 100
The effect of RA on ATF2 phosphorylation  
 
RA increases AP-1 transcriptional activity in B16 melanoma cells. 
However, RA does not increase the expression of any of the Fos or Jun family 
members, nor does it increase the binding activity of the AP-1 complex on a 
TRE. Since ATF2 can form a heterodimer with c-Jun, we hypothesized that RA 
increases AP-1 transcriptional activity by regulating ATF2 activation. B16 cells 
were treated for 48 h with or without various concentrations of RA. At the end of 
the treatment period all cells were harvested and analyzed for the phospho-ATF2 
level. This experiment (Fig. 17A) revealed that low concentration of RA (0.1 µM) 
was sensitive to inhibit ATF2 phosphorylation, and these data exhibited a 
decreasing trend in the amount of phospho-ATF2 protein level upon treatment 
with increasing concentrations of RA. Treatment of B16 cells with or without 10 
µM RA for different periods of time (Fig. 17B) showed that RA inhibited phospho-
ATF2 protein level by 60% after 48 h of treatment. However, RA treatment did 
not significantly alter the total ATF2 protein level over 48 h treatment (Fig. 17C). 
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Figure 17. Retinoic acid inhibited ATF2 phosphorylation in B16 
mouse melanoma cells 
 
B16 cells were treated with either vehicle (DMSO) or retinoic acid. At the 
end of the indicated incubation time, cells were harvested and 40 µg of protein 
from each group was analyzed by western blotting using polyclonal anti-
phospho-ATF2 antibody as described in Materials and Methods. The relative 
amount of phospho-ATF2 protein in each sample was determined by 
densitometry using GAPDH as an internal control. The data shown are from a 
representative experiment which was replicated three additional times with 
similar results. 
A. Cells were treated with the indicated concentrations of retinoic acid and 
harvested after 48 h of incubation. 
B. Cells were treated for the indicated time periods with 10 µM retinoic acid. 
C. Time course effect of 10 µM RA on total ATF2 level. 
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Figure 17 
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Figure 17 
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Signaling pathways involved in RA-dependent inhibition in ATF2 
phosphorylation 
  
Both p38 and JNK MAP kinases have been implicated in stimulation of 
ATF2 transcriptional activity by phosphorylation of ATF2 protein at both 
Threonine-69 and -71 sites. Therefore, we investigated their potential role in RA-
dependent inhibition in ATF2 phosphorylation. We directly examined the state of 
JNK and p38 activation in control and RA-treated cells through the use of total 
and phospho-specific JNK and p38 antibodies. There was no change in either 
total or phospho-specific (activated) JNK in control versus 24 h RA-treated B16 
cells, a time at which RA inhibits ATF2 phosphorylation (Fig. 14B). However, RA 
treatment inhibited phosphorylation (activation) of p38 MAP kinase by 70% after 
48h of treatment (Fig. 18A). 
 To determine whether inhibition of p38 leads to a decrease in ATF2 
phosphorylation, B16 cells were treated with or without 10 µM of the p38 MAPK 
selective inhibitor SB203580 for different periods of time and the relative amount 
of phospho-ATF2 determined by western blotting. The result (Fig. 18B) showed 
that the p38 MAPK inhibitor, SB203580, decreased phospho-ATF2 by 50% after 
48 h of treatment, which parallels the effect of RA on inhibition of ATF2 
phosphorylation. 
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Figure 18. The effect of RA on activation (phosphorylation) of 
JNK and p38 MAP kinases  
 
A. Cells were treated with 10 µM RA for the indicated times. Cells were 
then harvested, extracted and protein from each sample examined for total and 
phospho-specific JNK (Fig. 14B) or total and phospho-specific p38 (Fig. 18A) by 
western blotting as described in Materials and Methods. The results shown are 
representative of three individual experiments that gave similar results. 
 B. Cells were treated with or without 10 µM SB203580 for the indicated 
times. Cells were harvested, extracted and protein from each sample examined 
for phospho-specific ATF2 using western blotting as described in Materials and 
Methods. The result (Fig. 18B) shown is representative of three individual 
experiments that yielded similar results. 
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The requirement of AP-1 transcriptional activity for RA-dependent 
inhibition in ATF2 phosphorylation 
  
Jun:Fos and Jun:ATF2 heterodimers represent two classes of AP-1 
transcription complexes. They can influence each other’s activity as a result of 
intra-molecular interactions (Li et al., 1996; Papavassilion et al., 1995). These 
two dimers have dimer-specific DNA-binding site preferences which differ by one 
nucleotide. This variation in dimer partner and DNA binding site specificity is 
assumed to provide AP-1 transcription complexes with a high level of flexibility in 
gene regulation.  
 In these experiments, we determined whether AP-1 transcriptional activity 
was involved in the RA-dependent inhibition in ATF2 phosphorylation. Clones of 
B16 cells expressing a dominant negative c-Fos (A-Fos) and having markedly 
reduced AP-1 activity compared to clones not expressing A-Fos or wt B16 cells 
were treated with 10 µM RA for 24 h and 48 h. The amount of phospho-ATF2 
protein in control and treated cells was determined by western blotting. The 
results (Fig. 19A) indicate that 10 µM RA treatment for 48 h inhibited ATF2 
phosphorylation by 60% in wt B16 cells. However, RA treatment of A-Fos 
positive clones did not result in any decrease in ATF2 phosphorylation.  In 
contrast, a clone of B16 negative for A-Fos expression (A-Fos clone 27) treated 
with 10 µM RA for 48 h had phospho-ATF2 levels decreased to almost the same 
extent as wt B16 cells (Fig. 19B). 
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Figure 19. The effect of dominant negative c-fos on retinoic acid- 
dependent inhibition in ATF2 phosphorylation 
  
Wild type B16 cells and two A-Fos expressing clones 71 and 12 (A) and 
an non-expressing A-Fos clone 27 (B) were treated with or without 10 µM RA for 
24 h and 48 h. Cells were harvested and 40 µg of protein from each group was 
analyzed by western blotting using anti-phospho-ATF2 antibody as described in 
Materials and Methods. The autoradiogram (top) was scanned using a Molecular 
Dynamics densitometer, and after correcting for the amount of GAPDH protein, 
the relative amount of phospho-ATF2 in each sample was determined (bottom). 
The data shown are from a representative experiment which was replicated three 
additional times with similar results. 
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Retinoic acid increases B16 melanoma cells’ sensitivity to taxol 
  
To explore whether the inhibition of ATF2 phosphorylation induced by RA 
would affect the sensitivity of mouse melanoma cells to chemotherapeutic drugs, 
I selected taxol as a test agent. Taxol belongs to a family of drugs which are able 
to interfere with the normal progression of the cell cycle by blocking microtubule 
formation. B16 cells were either treated with 1 nM, 10 nM or 50 nM taxol for 16 h, 
or pre-treated with 10 µM RA for 48 h before adding the different concentrations 
of taxol. In order to avoid the influence of cell density on the effect of drugs, I 
seeded the group of cells without RA pre-treatment at 30% lower density than the 
group of cells with RA pre-treatment. We found (Fig. 20) that taxol induced a 
concentration-dependent inhibition in cell growth; pretreatment of cells with RA 
for 48 h led to a significant increase in sensitivity of B16 cells to taxol-induced cell 
growth inhibition. At 50, 10, and 1 nM, taxol decreased the viable cell number by 
55%, 48%, and 20%, respectively. However, when pretreatment of B16 cells with 
RA, the same doses of taxol could decrease the viable cell number by 82%, 
75%, and 52%, respectively. So 1 nM taxol was sufficient to decrease the viable 
cell number to the same extent as 50 nM taxol in the B16 cells when pretreated 
with 10 µM RA for 48 h. These observations suggest pretreatment with RA is 
able to increase the sensitivity of B16 melanoma cells to treatment by taxol. 
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Figure 20.  RA increases the sensitivity of B16 cells to taxol 
treatment. 
  
 One group (control group) of B16 cells were seeded at 2.4 × 104/35 mm 
culture dish, the other group (RA group) of B16 cells were seeded at 3.4 × 
104/35mm culture dish. Following a 24 h attachment period, control and RA 
group were treated with vehicle (DMSO) and 10 µM RA for 48 h, respectively. 
After 48 h of corresponding treatment, the cells were treated with different 
concentrations of taxol for 16 h. At the indicated times, the cell number in each 
group were counted through the use of crystal violet assay, then corrected by the 
initial cell number seeded. The data are presented as the mean ± SEM (error 
bars) of triplicate dishes. 
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Figure 20 
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DISCUSSION 
 
 
Unlike many human melanoma cell lines that are resistant to the effects of 
retinoic acid, B16 melanoma cells are induced by RA to undergo growth arrest in 
the G1 phase of the cell cycle and to increase the production of melanin, an 
indicator of differentiation (Rogelj et al., 1984). We have previously found that 
treatment of B16 mouse melanoma cells with all-trans retinoic acid induces a two 
to fourfold increase in AP-1 transcriptional activity and this increase appears to 
be required for growth arrest and differentiation (Huang et al., 2002).  RA does 
not increase the expression of any of the Fos or Jun family members, nor does it 
increase the binding activity of the AP-1 transcription complex (Desai et al., 
1997). In the second part of the research, I investigated the effect of RA on the 
phosphorylation of ATF2, another member of the AP-1 family.  
 A preliminary study showed that ATF2 protein was expressed at extremely 
high levels in B16 melanoma cells. The level of ATF2 mRNA is also higher in 
some clinical samples of human tumors than in normal tissues (Takeda et al., 
1991). Since genes encoding transcription factors are usually expressed at a 
very low level, ATF2 became an interesting study target in our melanoma model.  
Western blot results showed multiple bands of immunoreactive ATF2 protein, 
which led us to predict that ATF2 is a phospho-protein. Removal of the 
phosphate group by incubation of cell extracts with protein phosphatase-1 led to 
loss of immunoreactivity to the phospho-specific ATF2 antibody confirming our 
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hypothesis. To determine the relative importance of the ATF2 protein in the 
melanoma cells, I compared the expression level of ATF2 protein between the 
malignant melanoma cells and non-malignant immortalized mouse melanocytes. 
The results showed that there are 2-fold higher levels of ATF2 protein expressed 
in the malignant melanoma cells, relative to the non-malignant mouse 
melanocytes. Since stimulation of ATF2 transcriptional activity can result from its 
phosphorylation by the stress kinases p38 or JNK (Gupta et al., 1995), I also 
evaluated the relative amount of activated ATF2 which is expressed in both 
normal and malignant cell lines. Over 70% of total ATF2 protein is 
phosphorylated in the malignant B16 melanoma cells; while only 16% of total 
ATF2 protein is present in the active (phosphorylated) form in non-malignant 
mouse melanocytes. Although high activity of ATF2 has not been directly 
implicated in oncogenesis, our data suggest that high ATF2 activity might be 
important in reaching or maintaining the malignant state of melanomas. 
 The effect of RA on ATF2 expression and activation was investigated in 
the B16 melanoma cells. RA induced a concentration-dependent decrease in 
ATF2 phosphorylation, with 10 µM RA exhibiting the greatest inhibitory effect.  A 
time course study on the effect of RA on ATF2 activation showed that there is a 
20% decrease in ATF2 phosphorylation after 24 h of RA treatment, which 
reached 60% after 48 h of RA treatment. RA treatment did not significantly alter 
the total ATF2 protein level. The time course for RA inhibition of ATF2 
phosphorylation correlates with the effect of RA on AP-1 transcriptional activity, 
in which RA does not increase AP-1 activity until 24 h treatment, and reaches a 
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maximum by 48-56 h treatment. We suggest that these two forms (ATF2-
containing dimer and c-Fos containing dimer) of AP-1 transcription complexes 
are closely related in the effect of RA on B16 cells. 
 The transactivation activity of ATF2 is regulated post-translationally by 
phosphorylation, particularly by the JNK/SAPK and p38 groups of mitogen-
activated protein kinases (Gupta et al., 1995; Livingstone et al., 1995; Robinson, 
1997; van Dam et al., 1995). Therefore, I examined the possibility that RA 
interferes with the signaling pathway mediated by JNK and p38 MAP kinases.  
Short (4 h) and long (24 h)-term RA treatment did not affect the activation of JNK.  
However, 24 h of RA treatment inhibited p38 activation (phosphorylation) by 
30%, and by 70% after 48 h of treatment. These results suggest that a selective 
p38 MAP kinase inhibitor might mimic the action of RA.  Indeed we found that the 
selective p38 MAP kinase inhibitor, SB203580 (10 µM), inhibits ATF2 
phosphorylation by 50% after 48 h of treatment. Therefore, the results suggest 
that the signaling pathway involved in RA-dependent inhibition in ATF2 
phosphorylation is most likely p38 MAPK signaling pathway. 
 I also measured the effect of RA on ATF2 transcriptional activity by 
transient transfection with the CRE (TGACGTCA)-luciferase reporter gene. 
However, there was no significant change in luciferase activity between cells 
treated with and without RA. There are two possibilities to explain this result. 
First, ATF2 is expressed at an extremely high level in B16 melanoma cells, and 
the ability of RA to inhibit ATF2 phosphorylation is a slow process. Since the 
observation window for a transient transfection is short (24h), there might not 
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have been sufficient time for RA to decrease ATF2 phosphorylation to an extent 
which would affect its transcriptional activity.  Second, the response elements 
TRE and CRE have only one nucleotide difference. Even though ATF2 dimers 
prefer to bind to CRE, it might compete with the Jun:Fos dimer for binding with 
TRE.  Therefore, the effect of RA on ATF2 transcriptional activity could not be 
unambiguously tested by using the CRE-luciferase reporter gene in B16 cells. 
 Jun:Fos and Jun:ATF2 complexes represent two classes of AP-1 
transcription complexes.  Jun:Fos dimers bind with high affinity to the seven base 
pair consensus sequence TGAGTCA, while c-Jun:ATF2 heterodimers bind with 
high affinity to degenerate ATF sites with the consensus motif TGACNTCA. 
These two response elements only differ by one nucleotide.  In addition, Jun, Fos 
and ATF family members can bind to DNA upon association with Maf (Motohashi 
et al., 1997; Kerpola et al., 1996), C/EBP (Kageyama et al., 1991), and NFκB 
(Stein et al., 1993).  The expression of more than one AP-1 component is under 
positive and negative AP-1 control.  For example, Choi et al., 1997 found that 
ATF2 down-regulates hepatitis B virus promoter activity by the competition for 
the AP-1 binding site and the formation of the ATF2:Jun heterodimer.  Since I 
had previously established clones of B16 which stably express the dominant 
negative c-Fos, I investigated whether the ability of RA to inhibit ATF2 
phosphorylation was altered by the loss of AP-1 transcriptional activity.  In two 
B16 clones which have markedly depressed AP-1 activity, the ability of RA to 
inhibit ATF2 phosphorylation was lost, however in a neomycin resistant B16 
clone which does not express dominant negative Fos and has wild type AP-1 
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activity, RA decreased ATF2 phosphorylation. The role of AP-1 transcriptional 
activity in RA-induced inhibition of ATF2 phosphorylation is currently being 
investigated.  Our studies suggest that there is an intimate relationship between 
Fos containing AP-1 dimers and ATF2 containing dimers in B16 melanoma cells.  
RA can induce AP-1 transcriptional activity, and meanwhile, it inhibits ATF2 
phosphorylation.  Our results are in agreement with the study from Bhoumik et 
al., 2002.  They found that inhibition of ATF2 by an ATF2-derived peptide 
coincided with increased AP-1 activity. Thus, our working hypothesis is that RA 
alters the balance between ATF2 containing dimers and Fos containing AP-1 
dimers by inhibiting ATF2 phosphorylation, resulting in an increased AP-1 
transcriptional activity. How changes in the activity of these transcription factors 
lead to sensitization of melanoma to chemotherapeutic drugs is a subject of 
future investigation.   
 The hallmark of malignant melanoma is its resistance to chemotherapy 
and radiotherapy (Herlyn et al., 1992; Lu et al., 1994).  ATF2 and its activating 
protein kinase, p38, have been found to play an important role in the resistance 
of melanoma to radiation and chemotherapy (Ronai et al., 1998; Ivanov et al., 
2000). Hypophosphorylated or transcriptionally inactive forms of ATF2 elicit a 
silencing effect on TNFα expression, resulting in increased apoptosis (Ivanov et 
al., 1999).  When endogenous ATF2 expression is inhibited by the ATF-derived 
peptides, human melanoma cells are more sensitive to UV radiation or chemical 
treatment (Bhoumik et al., 2001).  In our study, we evaluated the ability of RA, 
which inhibits ATF2 activation (phosphorylation), to alter the sensitivity of B16 
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melanoma cells to taxol treatment. The mechanism by which RA is capable of 
increasing the sensitivity of B16 melanoma cells to taxol treatment is likely to 
involve ATF2 activity. It is possible that RA decreases the phosphorylation of 
ATF2, thus keeping the ATF2 protein inactive. Future studies that include using 
the mutant form of the ATF2, which renders ATF2 constitutively active, have 
been considered to confirm this hypothesis. Interfering with the inhibition of ATF2 
activation by RA is expected to result in an increase in the resistance of 
melanoma cells to chemotherapeutic drugs, such as taxol.  
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SUMMARY AND CONCLUSIONS 
 
 Retinoids show promise as therapeutic drugs for the prevention and 
treatment of non-melanoma skin cancer. They have also been shown to inhibit 
proliferation and induce differentiation of several mouse melanoma cell lines 
including B16, and a few human melanoma cell lines. However, many human 
melanoma cell lines are resistant to retinoids, and little is known about the 
molecular mechanisms responsible for this resistance. This dissertation mainly 
addressed the role of AP-1 transcription complexes in RA-dependent B16 
melanoma cell growth arrest and differentiation. The findings and conclusions 
are: 
 From the first part of my dissertation research: 
1. RA induces a slow, but sustained increase in AP-1 transcriptional activity 
in B16 melanoma cells. 
2. The mechanisms by which RA and phorbol dibutyrate increase AP-1 
transcriptional activity are different: PDB requires PKC enzyme activity to 
induce AP-1 activity; RA does not require PKC enzyme activity to induce 
AP-1 activity. 
3. Clones of B16 expressing dominant-negative Fos had a markedly 
decreased sensitivity to RA-induced inhibition of anchorage-dependent 
and –independent growth.  
4. The ability of RA to increase melanin production in wt B16 cells was 
completely lost in the clones of B16 expressing dominant-negative Fos.  
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Since RA does not increase the expression of any of the Fos and Jun 
family members, I studied the ATF2 protein, another member of the AP-1 
transcription complex, in the second part of my dissertation research. 
 
From the second part of my dissertation research: 
1. There is a much higher amount of ATF2 protein expressed in B16 
melanoma cells, compared to non-malignant mouse melanocytes. 
2. Over 70% of ATF2 protein is phosphorylated (active) in B16 melanoma 
cells; while only 16% of ATF2 protein is present in the active form 
(phosphorylated) in non-malignant mouse melanocytes. 
3. Treatment of B16 cells with RA for 48 h inhibits ATF2 phosphorylation by 
50%. 
4. The signaling pathway involved in RA-dependent inhibition of ATF2 
activation is most likely p38 MAP kinase, in which RA inhibits p38 
activation by 70% over 48 h of treatment. 
5.  ATF2 has been implicated in melanoma’s resistance to treatment. Our 
study found that pretreatment with RA, which inhibits ATF2 
phosphorylation, increases the sensitivity of B16 cells to the anticancer 
drug, taxol. 
 
 In conclusion, AP-1 transcriptional activity induced by RA appears to play 
an important role in the biological changes (growth inhibition and differentiation) 
mediated by this retinoid in B16 melanoma cells. ATF2 is another molecular 
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target of RA action. Previous reports indicate that ATF2 is involved in enhanced 
DNA repair and cell proliferation. RA-induced decrease in ATF2 activity may 
contribute to decreased proliferation and increased sensitivity to the 
chemotherapeutic agents.  
 Future studies are needed to answer the following questions: what is the 
role of ATF2 in melanoma development? Does RA increase the sensitivity of B16 
melanoma cells to taxol treatment and other chemotherapeutic drugs by 
decreasing ATF2 activity? How does RA inhibit p38 activation and is p38 the 
major regulatory mechanism responsible for RA-induced inhibition in ATF2 
phosphorylation? How does RA induce AP-1 activity (sustained) and what genes 
have altered expression that lead to growth arrest and differentiation mediated by 
this retinoid in B16 melanoma cells? More basic research is needed to 
understand these questions.  These investigations will likely lead to the discovery 
of new molecular targets for the treatment of melanoma. 
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